id	sid	tid	token	lemma	pos
gs-1727	1	1	georgian	georgian	ADJ
gs-1727	1	2	scientists/ქართველი	scientists/ქართველი	NOUN
gs-1727	1	3	მეცნიერები	მეცნიერები	NOUN
gs-1727	1	4	ტ.	ტ.	VERB
gs-1727	1	5	5	5	NUM
gs-1727	1	6	n	n	PRON
gs-1727	1	7	2	2	NUM
gs-1727	1	8	,	,	PUNCT
gs-1727	1	9	2023	2023	NUM
gs-1727	1	10	109	109	NUM
gs-1727	1	11	georgian	georgian	PROPN
gs-1727	1	12	scientists	scientist	NOUN
gs-1727	1	13	ქართველი	ქართველი	ADJ
gs-1727	1	14	მეცნიერები	მეცნიერები	PROPN
gs-1727	1	15	vol	vol	NOUN
gs-1727	1	16	.	.	PUNCT
gs-1727	2	1	5	5	NUM
gs-1727	2	2	issue	issue	NOUN
gs-1727	2	3	2	2	NUM
gs-1727	2	4	,	,	PUNCT
gs-1727	2	5	2023	2023	NUM
gs-1727	2	6	https://doi.org/10.52340/gs.2023.05.02.14	https://doi.org/10.52340/gs.2023.05.02.14	PRON
gs-1727	2	7	type	type	NOUN
gs-1727	2	8	i	i	PRON
gs-1727	2	9	and	and	CCONJ
gs-1727	2	10	type	type	NOUN
gs-1727	2	11	iib	iib	NOUN
gs-1727	2	12	autoimmunity	autoimmunity	NOUN
gs-1727	2	13	in	in	ADP
gs-1727	2	14	chronic	chronic	ADJ
gs-1727	2	15	spontaneous	spontaneous	ADJ
gs-1727	2	16	urticaria	urticaria	NOUN
gs-1727	2	17	patients	patient	NOUN
gs-1727	2	18	:	:	PUNCT
gs-1727	2	19	evaluating	evaluate	VERB
gs-1727	2	20	the	the	DET
gs-1727	2	21	clinical	clinical	ADJ
gs-1727	2	22	response	response	NOUN
gs-1727	2	23	to	to	ADP
gs-1727	2	24	omalizumab	omalizumab	NOUN
gs-1727	2	25	bidzina	bidzina	PROPN
gs-1727	2	26	kulumbegov1,2	kulumbegov1,2	PROPN
gs-1727	2	27	,	,	PUNCT
gs-1727	2	28	maia	maia	PROPN
gs-1727	2	29	gotua1	gotua1	PROPN
gs-1727	2	30	,	,	PUNCT
gs-1727	2	31	tinatin	tinatin	ADJ
gs-1727	2	32	chikovani2	chikovani2	NOUN
gs-1727	3	1	1center	1center	NUM
gs-1727	3	2	of	of	ADP
gs-1727	3	3	allergy	allergy	NOUN
gs-1727	3	4	and	and	CCONJ
gs-1727	3	5	immunology	immunology	NOUN
gs-1727	3	6	;	;	PUNCT
gs-1727	3	7	2tbilisi	2tbilisi	NUM
gs-1727	3	8	state	state	NOUN
gs-1727	3	9	medical	medical	ADJ
gs-1727	3	10	university	university	NOUN
gs-1727	3	11	abstract	abstract	NOUN
gs-1727	3	12	this	this	DET
gs-1727	3	13	study	study	NOUN
gs-1727	3	14	aimed	aim	VERB
gs-1727	3	15	to	to	PART
gs-1727	3	16	evaluate	evaluate	VERB
gs-1727	3	17	the	the	DET
gs-1727	3	18	clinical	clinical	ADJ
gs-1727	3	19	response	response	NOUN
gs-1727	3	20	to	to	ADP
gs-1727	3	21	omalizumab	omalizumab	NOUN
gs-1727	3	22	in	in	ADP
gs-1727	3	23	patients	patient	NOUN
gs-1727	3	24	with	with	ADP
gs-1727	3	25	type	type	NOUN
gs-1727	3	26	1	1	NUM
gs-1727	3	27	and	and	CCONJ
gs-1727	3	28	type	type	NOUN
gs-1727	3	29	iib	iib	NOUN
gs-1727	3	30	autoimmunity	autoimmunity	NOUN
gs-1727	3	31	suffering	suffer	VERB
gs-1727	3	32	from	from	ADP
gs-1727	3	33	chronic	chronic	ADJ
gs-1727	3	34	spontaneous	spontaneous	ADJ
gs-1727	3	35	urticaria	urticaria	NOUN
gs-1727	3	36	(	(	PUNCT
gs-1727	3	37	csu	csu	PROPN
gs-1727	3	38	)	)	PUNCT
gs-1727	3	39	and	and	CCONJ
gs-1727	3	40	to	to	PART
gs-1727	3	41	compare	compare	VERB
gs-1727	3	42	the	the	DET
gs-1727	3	43	difference	difference	NOUN
gs-1727	3	44	in	in	ADP
gs-1727	3	45	laboratory	laboratory	NOUN
gs-1727	3	46	data	datum	NOUN
gs-1727	3	47	.	.	PUNCT
gs-1727	4	1	a	a	DET
gs-1727	4	2	retrospective	retrospective	ADJ
gs-1727	4	3	study	study	NOUN
gs-1727	4	4	was	be	AUX
gs-1727	4	5	conducted	conduct	VERB
gs-1727	4	6	from	from	ADP
gs-1727	4	7	september	september	PROPN
gs-1727	4	8	2019	2019	NUM
gs-1727	4	9	to	to	ADP
gs-1727	4	10	december	december	PROPN
gs-1727	4	11	2022	2022	NUM
gs-1727	4	12	in	in	ADP
gs-1727	4	13	the	the	DET
gs-1727	4	14	center	center	NOUN
gs-1727	4	15	of	of	ADP
gs-1727	4	16	allergy	allergy	NOUN
gs-1727	4	17	and	and	CCONJ
gs-1727	4	18	immunology	immunology	NOUN
gs-1727	4	19	in	in	ADP
gs-1727	4	20	tbilisi	tbilisi	PROPN
gs-1727	4	21	,	,	PUNCT
gs-1727	4	22	georgia	georgia	PROPN
gs-1727	4	23	,	,	PUNCT
gs-1727	4	24	involving	involve	VERB
gs-1727	4	25	39	39	NUM
gs-1727	4	26	patients	patient	NOUN
gs-1727	4	27	(	(	PUNCT
gs-1727	4	28	95	95	NUM
gs-1727	4	29	%	%	NOUN
gs-1727	4	30	females	female	NOUN
gs-1727	4	31	,	,	PUNCT
gs-1727	4	32	5	5	NUM
gs-1727	4	33	%	%	NOUN
gs-1727	4	34	males	male	NOUN
gs-1727	4	35	,	,	PUNCT
gs-1727	4	36	average	average	ADJ
gs-1727	4	37	age	age	NOUN
gs-1727	4	38	35.82	35.82	NUM
gs-1727	4	39	years	year	NOUN
gs-1727	4	40	)	)	PUNCT
gs-1727	4	41	.	.	PUNCT
gs-1727	5	1	total	total	ADJ
gs-1727	5	2	ige	ige	PROPN
gs-1727	5	3	and	and	CCONJ
gs-1727	5	4	ana	ana	PROPN
gs-1727	5	5	antibodies	antibody	NOUN
gs-1727	5	6	were	be	AUX
gs-1727	5	7	taken	take	VERB
gs-1727	5	8	as	as	ADP
gs-1727	5	9	markers	marker	NOUN
gs-1727	5	10	of	of	ADP
gs-1727	5	11	autoimmunity	autoimmunity	NOUN
gs-1727	5	12	.	.	PUNCT
gs-1727	6	1	the	the	DET
gs-1727	6	2	study	study	NOUN
gs-1727	6	3	included	include	VERB
gs-1727	6	4	patients	patient	NOUN
gs-1727	6	5	who	who	PRON
gs-1727	6	6	still	still	ADV
gs-1727	6	7	had	have	VERB
gs-1727	6	8	high	high	ADJ
gs-1727	6	9	disease	disease	NOUN
gs-1727	6	10	activity	activity	NOUN
gs-1727	6	11	despite	despite	SCONJ
gs-1727	6	12	using	use	VERB
gs-1727	6	13	a	a	DET
gs-1727	6	14	fourfold	fourfold	ADJ
gs-1727	6	15	dose	dose	NOUN
gs-1727	6	16	of	of	ADP
gs-1727	6	17	non	non	ADJ
gs-1727	6	18	-	-	ADJ
gs-1727	6	19	sedating	sedating	ADJ
gs-1727	6	20	antihistamines	antihistamine	NOUN
gs-1727	6	21	.	.	PUNCT
gs-1727	7	1	patients	patient	NOUN
gs-1727	7	2	were	be	AUX
gs-1727	7	3	prescribed	prescribe	VERB
gs-1727	7	4	omalizumab	omalizumab	NOUN
gs-1727	7	5	according	accord	VERB
gs-1727	7	6	to	to	ADP
gs-1727	7	7	international	international	ADJ
gs-1727	7	8	guidelines	guideline	NOUN
gs-1727	7	9	with	with	ADP
gs-1727	7	10	an	an	DET
gs-1727	7	11	interval	interval	NOUN
gs-1727	7	12	of	of	ADP
gs-1727	7	13	4	4	NUM
gs-1727	7	14	weeks	week	NOUN
gs-1727	7	15	for	for	ADP
gs-1727	7	16	at	at	ADV
gs-1727	7	17	least	least	ADV
gs-1727	7	18	3	3	NUM
gs-1727	7	19	months	month	NOUN
gs-1727	7	20	.	.	PUNCT
gs-1727	8	1	disease	disease	NOUN
gs-1727	8	2	activity	activity	NOUN
gs-1727	8	3	was	be	AUX
gs-1727	8	4	determined	determine	VERB
gs-1727	8	5	using	use	VERB
gs-1727	8	6	the	the	DET
gs-1727	8	7	urticaria	urticaria	NOUN
gs-1727	8	8	activity	activity	NOUN
gs-1727	8	9	score	score	NOUN
gs-1727	8	10	(	(	PUNCT
gs-1727	8	11	uas7	uas7	ADJ
gs-1727	8	12	)	)	PUNCT
gs-1727	8	13	,	,	PUNCT
gs-1727	8	14	and	and	CCONJ
gs-1727	8	15	patients	patient	NOUN
gs-1727	8	16	were	be	AUX
gs-1727	8	17	divided	divide	VERB
gs-1727	8	18	into	into	ADP
gs-1727	8	19	three	three	NUM
gs-1727	8	20	groups	group	NOUN
gs-1727	8	21	according	accord	VERB
gs-1727	8	22	to	to	ADP
gs-1727	8	23	csu	csu	NOUN
gs-1727	8	24	activity	activity	NOUN
gs-1727	8	25	:	:	PUNCT
gs-1727	8	26	low	low	ADJ
gs-1727	8	27	,	,	PUNCT
gs-1727	8	28	moderate	moderate	ADJ
gs-1727	8	29	,	,	PUNCT
gs-1727	8	30	and	and	CCONJ
gs-1727	8	31	high	high	ADJ
gs-1727	8	32	disease	disease	NOUN
gs-1727	8	33	activity	activity	NOUN
gs-1727	8	34	.	.	PUNCT
gs-1727	9	1	response	response	NOUN
gs-1727	9	2	to	to	ADP
gs-1727	9	3	omalizumab	omalizumab	NOUN
gs-1727	9	4	was	be	AUX
gs-1727	9	5	assessed	assess	VERB
gs-1727	9	6	as	as	ADP
gs-1727	9	7	nonresponders	nonresponder	NOUN
gs-1727	9	8	,	,	PUNCT
gs-1727	9	9	partial	partial	ADJ
gs-1727	9	10	responders	responder	NOUN
gs-1727	9	11	,	,	PUNCT
gs-1727	9	12	and	and	CCONJ
gs-1727	9	13	complete	complete	ADJ
gs-1727	9	14	responders	responder	NOUN
gs-1727	9	15	.	.	PUNCT
gs-1727	10	1	the	the	DET
gs-1727	10	2	results	result	NOUN
gs-1727	10	3	showed	show	VERB
gs-1727	10	4	that	that	DET
gs-1727	10	5	type	type	NOUN
gs-1727	10	6	i	i	PRON
gs-1727	10	7	autoimmunity	autoimmunity	NOUN
gs-1727	10	8	had	have	VERB
gs-1727	10	9	a	a	DET
gs-1727	10	10	higher	high	ADJ
gs-1727	10	11	percentage	percentage	NOUN
gs-1727	10	12	of	of	ADP
gs-1727	10	13	complete	complete	ADJ
gs-1727	10	14	responders	responder	NOUN
gs-1727	10	15	than	than	ADP
gs-1727	10	16	type	type	NOUN
gs-1727	10	17	iib	iib	NOUN
gs-1727	10	18	(	(	PUNCT
gs-1727	10	19	55.5	55.5	NUM
gs-1727	10	20	%	%	NOUN
gs-1727	10	21	vs.	vs.	ADP
gs-1727	10	22	18.3	18.3	NUM
gs-1727	10	23	%	%	NOUN
gs-1727	10	24	)	)	PUNCT
gs-1727	10	25	.	.	PUNCT
gs-1727	11	1	nonresponder	nonresponder	NOUN
gs-1727	11	2	rates	rate	NOUN
gs-1727	11	3	were	be	AUX
gs-1727	11	4	higher	high	ADJ
gs-1727	11	5	in	in	ADP
gs-1727	11	6	type	type	NOUN
gs-1727	11	7	iib	iib	NOUN
gs-1727	11	8	than	than	ADP
gs-1727	11	9	in	in	ADP
gs-1727	11	10	type	type	NOUN
gs-1727	11	11	i	i	NOUN
gs-1727	11	12	(	(	PUNCT
gs-1727	11	13	72.7	72.7	NUM
gs-1727	11	14	%	%	NOUN
gs-1727	11	15	vs.	vs.	ADP
gs-1727	11	16	18.5	18.5	NUM
gs-1727	11	17	%	%	NOUN
gs-1727	11	18	)	)	PUNCT
gs-1727	11	19	.	.	PUNCT
gs-1727	12	1	the	the	DET
gs-1727	12	2	median	median	ADJ
gs-1727	12	3	total	total	ADJ
gs-1727	12	4	ige	ige	PROPN
gs-1727	12	5	levels	level	NOUN
gs-1727	12	6	were	be	AUX
gs-1727	12	7	significantly	significantly	ADV
gs-1727	12	8	higher	high	ADJ
gs-1727	12	9	in	in	ADP
gs-1727	12	10	type	type	NOUN
gs-1727	12	11	i	i	PRON
gs-1727	12	12	than	than	ADP
gs-1727	12	13	in	in	ADP
gs-1727	12	14	type	type	NOUN
gs-1727	12	15	iib	iib	NOUN
gs-1727	12	16	(	(	PUNCT
gs-1727	12	17	138	138	NUM
gs-1727	12	18	vs.	vs.	ADP
gs-1727	12	19	23.95	23.95	NUM
gs-1727	12	20	ku	ku	PROPN
gs-1727	12	21	/	/	SYM
gs-1727	12	22	i	i	PROPN
gs-1727	12	23	)	)	PUNCT
gs-1727	12	24	.	.	PUNCT
gs-1727	13	1	the	the	DET
gs-1727	13	2	median	median	ADJ
gs-1727	13	3	duration	duration	NOUN
gs-1727	13	4	of	of	ADP
gs-1727	13	5	the	the	DET
gs-1727	13	6	disease	disease	NOUN
gs-1727	13	7	was	be	AUX
gs-1727	13	8	significantly	significantly	ADV
gs-1727	13	9	shorter	short	ADJ
gs-1727	13	10	in	in	ADP
gs-1727	13	11	type	type	NOUN
gs-1727	13	12	i	i	PRON
gs-1727	13	13	than	than	ADP
gs-1727	13	14	in	in	ADP
gs-1727	13	15	type	type	NOUN
gs-1727	13	16	iib	iib	NOUN
gs-1727	13	17	(	(	PUNCT
gs-1727	13	18	9	9	NUM
gs-1727	13	19	vs.	vs.	ADP
gs-1727	13	20	27	27	NUM
gs-1727	13	21	months	month	NOUN
gs-1727	13	22	)	)	PUNCT
gs-1727	13	23	.	.	PUNCT
gs-1727	14	1	no	no	DET
gs-1727	14	2	significant	significant	ADJ
gs-1727	14	3	differences	difference	NOUN
gs-1727	14	4	were	be	AUX
gs-1727	14	5	found	find	VERB
gs-1727	14	6	between	between	ADP
gs-1727	14	7	the	the	DET
gs-1727	14	8	two	two	NUM
gs-1727	14	9	groups	group	NOUN
gs-1727	14	10	regarding	regard	VERB
gs-1727	14	11	age	age	NOUN
gs-1727	14	12	,	,	PUNCT
gs-1727	14	13	angioedema	angioedema	VERB
gs-1727	14	14	,	,	PUNCT
gs-1727	14	15	crp	crp	PROPN
gs-1727	14	16	levels	level	NOUN
gs-1727	14	17	,	,	PUNCT
gs-1727	14	18	h.	h.	PROPN
gs-1727	14	19	pylori	pylori	NOUN
gs-1727	14	20	infection	infection	NOUN
gs-1727	14	21	rates	rate	NOUN
gs-1727	14	22	,	,	PUNCT
gs-1727	14	23	anti	anti	ADJ
gs-1727	14	24	-	-	ADJ
gs-1727	14	25	tpo	tpo	ADJ
gs-1727	14	26	igg	igg	PROPN
gs-1727	14	27	levels	levels	PROPN
gs-1727	14	28	,	,	PUNCT
gs-1727	14	29	eosinopenia	eosinopenia	NOUN
gs-1727	14	30	,	,	PUNCT
gs-1727	14	31	and	and	CCONJ
gs-1727	14	32	basopenia	basopenia	NOUN
gs-1727	14	33	.	.	PUNCT
gs-1727	15	1	in	in	ADP
gs-1727	15	2	conclusion	conclusion	NOUN
gs-1727	15	3	,	,	PUNCT
gs-1727	15	4	this	this	DET
gs-1727	15	5	study	study	NOUN
gs-1727	15	6	suggests	suggest	VERB
gs-1727	15	7	that	that	SCONJ
gs-1727	15	8	the	the	DET
gs-1727	15	9	clinical	clinical	ADJ
gs-1727	15	10	response	response	NOUN
gs-1727	15	11	to	to	ADP
gs-1727	15	12	omalizumab	omalizumab	NOUN
gs-1727	15	13	differs	differ	NOUN
gs-1727	15	14	depending	depend	VERB
gs-1727	15	15	on	on	ADP
gs-1727	15	16	the	the	DET
gs-1727	15	17	type	type	NOUN
gs-1727	15	18	of	of	ADP
gs-1727	15	19	autoimmunity	autoimmunity	NOUN
gs-1727	15	20	.	.	PUNCT
gs-1727	16	1	type	type	NOUN
gs-1727	16	2	i	i	PRON
gs-1727	16	3	autoimmunity	autoimmunity	NOUN
gs-1727	16	4	patients	patient	NOUN
gs-1727	16	5	had	have	VERB
gs-1727	16	6	a	a	DET
gs-1727	16	7	better	well	ADJ
gs-1727	16	8	response	response	NOUN
gs-1727	16	9	to	to	ADP
gs-1727	16	10	omalizumab	omalizumab	NOUN
gs-1727	16	11	than	than	ADP
gs-1727	16	12	type	type	NOUN
gs-1727	16	13	iib	iib	NOUN
gs-1727	16	14	.	.	PUNCT
gs-1727	17	1	the	the	DET
gs-1727	17	2	median	median	ADJ
gs-1727	17	3	duration	duration	NOUN
gs-1727	17	4	of	of	ADP
gs-1727	17	5	the	the	DET
gs-1727	17	6	disease	disease	NOUN
gs-1727	17	7	was	be	AUX
gs-1727	17	8	significantly	significantly	ADV
gs-1727	17	9	shorter	short	ADJ
gs-1727	17	10	in	in	ADP
gs-1727	17	11	type	type	NOUN
gs-1727	17	12	i	i	PRON
gs-1727	17	13	than	than	ADP
gs-1727	17	14	in	in	ADP
gs-1727	17	15	type	type	NOUN
gs-1727	17	16	iib	iib	NOUN
gs-1727	17	17	.	.	PUNCT
gs-1727	18	1	further	further	PROPN
gs-1727	18	2	studies	study	NOUN
gs-1727	18	3	are	be	AUX
gs-1727	18	4	needed	need	VERB
gs-1727	18	5	to	to	PART
gs-1727	18	6	evaluate	evaluate	VERB
gs-1727	18	7	the	the	DET
gs-1727	18	8	mechanism	mechanism	NOUN
gs-1727	18	9	underlying	underlie	VERB
gs-1727	18	10	the	the	DET
gs-1727	18	11	difference	difference	NOUN
gs-1727	18	12	in	in	ADP
gs-1727	18	13	response	response	NOUN
gs-1727	18	14	to	to	ADP
gs-1727	18	15	omalizumab	omalizumab	NOUN
gs-1727	18	16	and	and	CCONJ
gs-1727	18	17	the	the	DET
gs-1727	18	18	use	use	NOUN
gs-1727	18	19	of	of	ADP
gs-1727	18	20	different	different	ADJ
gs-1727	18	21	treatment	treatment	NOUN
gs-1727	18	22	options	option	NOUN
gs-1727	18	23	for	for	ADP
gs-1727	18	24	patients	patient	NOUN
gs-1727	18	25	with	with	ADP
gs-1727	18	26	different	different	ADJ
gs-1727	18	27	types	type	NOUN
gs-1727	18	28	of	of	ADP
gs-1727	18	29	autoimmunity	autoimmunity	NOUN
gs-1727	18	30	.	.	PUNCT
gs-1727	19	1	keywords	keyword	NOUN
gs-1727	19	2	:	:	PUNCT
gs-1727	19	3	chronic	chronic	ADJ
gs-1727	19	4	spontaneous	spontaneous	ADJ
gs-1727	19	5	urticaria	urticaria	NOUN
gs-1727	19	6	,	,	PUNCT
gs-1727	19	7	omalizumab	omalizumab	NOUN
gs-1727	19	8	,	,	PUNCT
gs-1727	19	9	type	type	NOUN
gs-1727	19	10	i	i	PRON
gs-1727	19	11	and	and	CCONJ
gs-1727	19	12	type	type	NOUN
gs-1727	19	13	iib	iib	PROPN
gs-1727	19	14	autoimmunity	autoimmunity	NOUN
gs-1727	19	15	georgian	georgian	PROPN
gs-1727	19	16	scientists/ქართველი	scientists/ქართველი	NOUN
gs-1727	19	17	მეცნიერები	მეცნიერები	NOUN
gs-1727	19	18	ტ.	ტ.	VERB
gs-1727	19	19	5	5	NUM
gs-1727	19	20	n	n	PRON
gs-1727	19	21	2	2	NUM
gs-1727	19	22	,	,	PUNCT
gs-1727	19	23	2023	2023	NUM
gs-1727	19	24	110	110	NUM
gs-1727	19	25	introduction	introduction	NOUN
gs-1727	19	26	omalizumab	omalizumab	NOUN
gs-1727	19	27	has	have	AUX
gs-1727	19	28	emerged	emerge	VERB
gs-1727	19	29	as	as	ADP
gs-1727	19	30	a	a	DET
gs-1727	19	31	crucial	crucial	ADJ
gs-1727	19	32	therapy	therapy	NOUN
gs-1727	19	33	for	for	ADP
gs-1727	19	34	individuals	individual	NOUN
gs-1727	19	35	suffering	suffer	VERB
gs-1727	19	36	from	from	ADP
gs-1727	19	37	chronic	chronic	ADJ
gs-1727	19	38	spontaneous	spontaneous	ADJ
gs-1727	19	39	urticaria	urticaria	NOUN
gs-1727	19	40	(	(	PUNCT
gs-1727	19	41	csu	csu	PROPN
gs-1727	19	42	)	)	PUNCT
gs-1727	19	43	who	who	PRON
gs-1727	19	44	do	do	AUX
gs-1727	19	45	not	not	PART
gs-1727	19	46	respond	respond	VERB
gs-1727	19	47	to	to	ADP
gs-1727	19	48	antihistamines	antihistamine	NOUN
gs-1727	19	49	,	,	PUNCT
gs-1727	19	50	even	even	ADV
gs-1727	19	51	when	when	SCONJ
gs-1727	19	52	administered	administer	VERB
gs-1727	19	53	in	in	ADP
gs-1727	19	54	doses	dose	NOUN
gs-1727	19	55	higher	high	ADJ
gs-1727	19	56	than	than	ADP
gs-1727	19	57	those	those	PRON
gs-1727	19	58	recommended	recommend	VERB
gs-1727	19	59	by	by	ADP
gs-1727	19	60	the	the	DET
gs-1727	19	61	manufacturer1	manufacturer1	PROPN
gs-1727	19	62	.	.	PUNCT
gs-1727	20	1	around	around	ADP
gs-1727	20	2	70	70	NUM
gs-1727	20	3	%	%	NOUN
gs-1727	20	4	of	of	ADP
gs-1727	20	5	patients	patient	NOUN
gs-1727	20	6	(	(	PUNCT
gs-1727	20	7	referred	refer	VERB
gs-1727	20	8	to	to	ADP
gs-1727	20	9	as	as	ADP
gs-1727	20	10	fast	fast	ADJ
gs-1727	20	11	responders	responder	NOUN
gs-1727	20	12	)	)	PUNCT
gs-1727	20	13	experience	experience	VERB
gs-1727	20	14	a	a	DET
gs-1727	20	15	quick	quick	ADJ
gs-1727	20	16	decline	decline	NOUN
gs-1727	20	17	in	in	ADP
gs-1727	20	18	uas7	uas7	PROPN
gs-1727	20	19	levels	level	NOUN
gs-1727	20	20	when	when	SCONJ
gs-1727	20	21	treated	treat	VERB
gs-1727	20	22	with	with	ADP
gs-1727	20	23	anti	anti	ADJ
gs-1727	20	24	-	-	ADJ
gs-1727	20	25	ige	ige	ADJ
gs-1727	20	26	,	,	PUNCT
gs-1727	20	27	whereas	whereas	SCONJ
gs-1727	20	28	an	an	DET
gs-1727	20	29	additional	additional	ADJ
gs-1727	20	30	15	15	NUM
gs-1727	20	31	%	%	NOUN
gs-1727	20	32	of	of	ADP
gs-1727	20	33	patients	patient	NOUN
gs-1727	20	34	(	(	PUNCT
gs-1727	20	35	called	call	VERB
gs-1727	20	36	slow	slow	ADJ
gs-1727	20	37	responders	responder	NOUN
gs-1727	20	38	)	)	PUNCT
gs-1727	20	39	have	have	VERB
gs-1727	20	40	a	a	DET
gs-1727	20	41	similar	similar	ADJ
gs-1727	20	42	response	response	NOUN
gs-1727	20	43	over	over	ADP
gs-1727	20	44	3	3	NUM
gs-1727	20	45	-	-	SYM
gs-1727	20	46	4	4	NUM
gs-1727	20	47	months	month	NOUN
gs-1727	20	48	.	.	PUNCT
gs-1727	21	1	the	the	DET
gs-1727	21	2	remaining	remain	VERB
gs-1727	21	3	15	15	NUM
gs-1727	21	4	%	%	NOUN
gs-1727	21	5	appear	appear	VERB
gs-1727	21	6	to	to	PART
gs-1727	21	7	be	be	AUX
gs-1727	21	8	resistant	resistant	ADJ
gs-1727	21	9	to	to	ADP
gs-1727	21	10	the	the	DET
gs-1727	21	11	treatment2	treatment2	NOUN
gs-1727	21	12	.	.	PUNCT
gs-1727	22	1	there	there	PRON
gs-1727	22	2	have	have	AUX
gs-1727	22	3	been	be	AUX
gs-1727	22	4	several	several	ADJ
gs-1727	22	5	studies	study	NOUN
gs-1727	22	6	conducted	conduct	VERB
gs-1727	22	7	in	in	ADP
gs-1727	22	8	recent	recent	ADJ
gs-1727	22	9	times	time	NOUN
gs-1727	22	10	which	which	PRON
gs-1727	22	11	have	have	AUX
gs-1727	22	12	demonstrated	demonstrate	VERB
gs-1727	22	13	a	a	DET
gs-1727	22	14	correlation	correlation	NOUN
gs-1727	22	15	between	between	ADP
gs-1727	22	16	the	the	DET
gs-1727	22	17	initial	initial	ADJ
gs-1727	22	18	total	total	ADJ
gs-1727	22	19	ige	ige	PROPN
gs-1727	22	20	levels	level	NOUN
gs-1727	22	21	and	and	CCONJ
gs-1727	22	22	the	the	DET
gs-1727	22	23	clinical	clinical	ADJ
gs-1727	22	24	response	response	NOUN
gs-1727	22	25	observed	observe	VERB
gs-1727	22	26	after	after	ADP
gs-1727	22	27	treatment	treatment	NOUN
gs-1727	22	28	with	with	ADP
gs-1727	22	29	the	the	DET
gs-1727	22	30	drug	drug	NOUN
gs-1727	22	31	3,4	3,4	NUM
gs-1727	22	32	.	.	PUNCT
gs-1727	23	1	identifying	identify	VERB
gs-1727	23	2	an	an	DET
gs-1727	23	3	ige	ige	NOUN
gs-1727	23	4	-	-	PUNCT
gs-1727	23	5	mediated	mediate	VERB
gs-1727	23	6	auto	auto	NOUN
gs-1727	23	7	-	-	PUNCT
gs-1727	23	8	allergic	allergic	ADJ
gs-1727	23	9	mechanism	mechanism	NOUN
gs-1727	23	10	in	in	ADP
gs-1727	23	11	many	many	ADJ
gs-1727	23	12	csu	csu	NOUN
gs-1727	23	13	patients	patient	NOUN
gs-1727	23	14	explains	explain	VERB
gs-1727	23	15	the	the	DET
gs-1727	23	16	rapid	rapid	ADJ
gs-1727	23	17	response	response	NOUN
gs-1727	23	18	observed	observe	VERB
gs-1727	23	19	in	in	ADP
gs-1727	23	20	severely	severely	ADV
gs-1727	23	21	affected	affect	VERB
gs-1727	23	22	individuals	individual	NOUN
gs-1727	23	23	upon	upon	SCONJ
gs-1727	23	24	being	be	AUX
gs-1727	23	25	treated	treat	VERB
gs-1727	23	26	with	with	ADP
gs-1727	23	27	omalizumab5	omalizumab5	PROPN
gs-1727	23	28	.	.	PUNCT
gs-1727	24	1	at	at	ADP
gs-1727	24	2	the	the	DET
gs-1727	24	3	same	same	ADJ
gs-1727	24	4	time	time	NOUN
gs-1727	24	5	,	,	PUNCT
gs-1727	24	6	there	there	PRON
gs-1727	24	7	are	be	VERB
gs-1727	24	8	data	datum	NOUN
gs-1727	24	9	on	on	ADP
gs-1727	24	10	type	type	NOUN
gs-1727	24	11	iib	iib	NOUN
gs-1727	24	12	autoimmunity	autoimmunity	NOUN
gs-1727	24	13	with	with	ADP
gs-1727	24	14	a	a	DET
gs-1727	24	15	poor	poor	ADJ
gs-1727	24	16	clinical	clinical	ADJ
gs-1727	24	17	response	response	NOUN
gs-1727	24	18	to	to	ADP
gs-1727	24	19	omalizumab	omalizumab	NOUN
gs-1727	24	20	and	and	CCONJ
gs-1727	24	21	a	a	DET
gs-1727	24	22	good	good	ADJ
gs-1727	24	23	response	response	NOUN
gs-1727	24	24	to	to	PART
gs-1727	24	25	cyclosporine	cyclosporine	VERB
gs-1727	24	26	6	6	NUM
gs-1727	24	27	.	.	PUNCT
gs-1727	24	28	based	base	VERB
gs-1727	24	29	on	on	ADP
gs-1727	24	30	two	two	NUM
gs-1727	24	31	types	type	NOUN
gs-1727	24	32	of	of	ADP
gs-1727	24	33	mast	mast	NOUN
gs-1727	24	34	cell	cell	NOUN
gs-1727	24	35	degranulating	degranulating	NOUN
gs-1727	24	36	signals	signal	NOUN
gs-1727	24	37	,	,	PUNCT
gs-1727	24	38	two	two	NUM
gs-1727	24	39	endotypes	endotype	NOUN
gs-1727	24	40	of	of	ADP
gs-1727	24	41	csu	csu	PROPN
gs-1727	24	42	,	,	PUNCT
gs-1727	24	43	auto	auto	NOUN
gs-1727	24	44	-	-	PUNCT
gs-1727	24	45	allergic	allergic	NOUN
gs-1727	24	46	and	and	CCONJ
gs-1727	24	47	autoimmune	autoimmune	ADJ
gs-1727	24	48	,	,	PUNCT
gs-1727	24	49	are	be	AUX
gs-1727	24	50	proposed	propose	VERB
gs-1727	24	51	.	.	PUNCT
gs-1727	25	1	the	the	DET
gs-1727	25	2	first	first	ADJ
gs-1727	25	3	is	be	AUX
gs-1727	25	4	known	know	VERB
gs-1727	25	5	as	as	ADP
gs-1727	25	6	type	type	NOUN
gs-1727	25	7	i	i	PRON
gs-1727	25	8	autoimmune	autoimmune	PROPN
gs-1727	25	9	csu	csu	AUX
gs-1727	25	10	mediated	mediate	VERB
gs-1727	25	11	by	by	ADP
gs-1727	25	12	ige	ige	PROPN
gs-1727	25	13	autoantibodies	autoantibody	NOUN
gs-1727	25	14	and	and	CCONJ
gs-1727	25	15	the	the	DET
gs-1727	25	16	second	second	ADJ
gs-1727	25	17	–	–	PUNCT
gs-1727	25	18	aicsu	aicsu	ADJ
gs-1727	25	19	,	,	PUNCT
gs-1727	25	20	known	know	VERB
gs-1727	25	21	as	as	ADP
gs-1727	25	22	type	type	NOUN
gs-1727	25	23	iib	iib	PROPN
gs-1727	25	24	autoimmune	autoimmune	PROPN
gs-1727	25	25	csu	csu	PROPN
gs-1727	25	26	,	,	PUNCT
gs-1727	25	27	in	in	ADP
gs-1727	25	28	which	which	PRON
gs-1727	25	29	igg	igg	NOUN
gs-1727	25	30	autoantibodies	autoantibody	NOUN
gs-1727	25	31	,	,	PUNCT
gs-1727	25	32	and	and	CCONJ
gs-1727	25	33	probably	probably	ADV
gs-1727	25	34	igm	igm	PROPN
gs-1727	25	35	and	and	CCONJ
gs-1727	25	36	iga	iga	PROPN
gs-1727	25	37	,	,	PUNCT
gs-1727	25	38	are	be	AUX
gs-1727	25	39	responsible	responsible	ADJ
gs-1727	25	40	for	for	ADP
gs-1727	25	41	direct	direct	ADJ
gs-1727	25	42	activation	activation	NOUN
gs-1727	25	43	of	of	ADP
gs-1727	25	44	mast	mast	NOUN
gs-1727	25	45	cells	cell	NOUN
gs-1727	25	46	through	through	ADP
gs-1727	25	47	binding	bind	VERB
gs-1727	25	48	to	to	ADP
gs-1727	25	49	high	high	ADJ
gs-1727	25	50	-	-	PUNCT
gs-1727	25	51	affinity	affinity	NOUN
gs-1727	25	52	ige	ige	NOUN
gs-1727	25	53	receptors	receptor	NOUN
gs-1727	25	54	.	.	PUNCT
gs-1727	26	1	according	accord	VERB
gs-1727	26	2	to	to	ADP
gs-1727	26	3	existing	exist	VERB
gs-1727	26	4	studies	study	NOUN
gs-1727	26	5	,	,	PUNCT
gs-1727	26	6	total	total	ADJ
gs-1727	26	7	ige	ige	PROPN
gs-1727	26	8	,	,	PUNCT
gs-1727	26	9	anti	anti	ADJ
gs-1727	26	10	-	-	ADJ
gs-1727	26	11	tpo	tpo	NOUN
gs-1727	26	12	,	,	PUNCT
gs-1727	26	13	autologous	autologous	ADJ
gs-1727	26	14	serum	serum	NOUN
gs-1727	26	15	skin	skin	NOUN
gs-1727	26	16	test	test	NOUN
gs-1727	26	17	(	(	PUNCT
gs-1727	26	18	asst	asst	NOUN
gs-1727	26	19	)	)	PUNCT
gs-1727	26	20	,	,	PUNCT
gs-1727	26	21	basophil	basophil	VERB
gs-1727	26	22	histamine	histamine	NOUN
gs-1727	26	23	release	release	NOUN
gs-1727	26	24	assay	assay	NOUN
gs-1727	26	25	(	(	PUNCT
gs-1727	26	26	bhra	bhra	PROPN
gs-1727	26	27	)	)	PUNCT
gs-1727	26	28	,	,	PUNCT
gs-1727	26	29	and	and	CCONJ
gs-1727	26	30	other	other	ADJ
gs-1727	26	31	tests	test	NOUN
gs-1727	26	32	have	have	AUX
gs-1727	26	33	been	be	AUX
gs-1727	26	34	used	use	VERB
gs-1727	26	35	to	to	PART
gs-1727	26	36	determine	determine	VERB
gs-1727	26	37	mainly	mainly	ADV
gs-1727	26	38	two	two	NUM
gs-1727	26	39	types	type	NOUN
gs-1727	26	40	of	of	ADP
gs-1727	26	41	autoimmunity	autoimmunity	NOUN
gs-1727	26	42	mechanisms7	mechanisms7	NOUN
gs-1727	26	43	.	.	PUNCT
gs-1727	27	1	it	it	PRON
gs-1727	27	2	is	be	AUX
gs-1727	27	3	important	important	ADJ
gs-1727	27	4	to	to	PART
gs-1727	27	5	find	find	VERB
gs-1727	27	6	simple	simple	ADJ
gs-1727	27	7	and	and	CCONJ
gs-1727	27	8	cost	cost	NOUN
gs-1727	27	9	-	-	PUNCT
gs-1727	27	10	effective	effective	ADJ
gs-1727	27	11	markers	marker	NOUN
gs-1727	27	12	to	to	PART
gs-1727	27	13	distinguish	distinguish	VERB
gs-1727	27	14	between	between	ADP
gs-1727	27	15	forms	form	NOUN
gs-1727	27	16	of	of	ADP
gs-1727	27	17	autoimmunity	autoimmunity	NOUN
gs-1727	27	18	.	.	PUNCT
gs-1727	28	1	we	we	PRON
gs-1727	28	2	used	use	VERB
gs-1727	28	3	total	total	ADJ
gs-1727	28	4	ige	ige	PROPN
gs-1727	28	5	and	and	CCONJ
gs-1727	28	6	ana	ana	PROPN
gs-1727	28	7	antibodies	antibodie	VERB
gs-1727	28	8	in	in	ADP
gs-1727	28	9	our	our	PRON
gs-1727	28	10	study	study	NOUN
gs-1727	28	11	.	.	PUNCT
gs-1727	29	1	our	our	PRON
gs-1727	29	2	study	study	NOUN
gs-1727	29	3	aims	aim	VERB
gs-1727	29	4	to	to	PART
gs-1727	29	5	evaluate	evaluate	VERB
gs-1727	29	6	the	the	DET
gs-1727	29	7	clinical	clinical	ADJ
gs-1727	29	8	response	response	NOUN
gs-1727	29	9	to	to	ADP
gs-1727	29	10	omalizumab	omalizumab	NOUN
gs-1727	29	11	in	in	ADP
gs-1727	29	12	patients	patient	NOUN
gs-1727	29	13	with	with	ADP
gs-1727	29	14	type	type	NOUN
gs-1727	29	15	i	i	PRON
gs-1727	29	16	and	and	CCONJ
gs-1727	29	17	type	type	NOUN
gs-1727	29	18	iib	iib	PROPN
gs-1727	29	19	autoimmune	autoimmune	ADJ
gs-1727	29	20	disease	disease	NOUN
gs-1727	29	21	and	and	CCONJ
gs-1727	29	22	the	the	DET
gs-1727	29	23	difference	difference	NOUN
gs-1727	29	24	in	in	ADP
gs-1727	29	25	laboratory	laboratory	NOUN
gs-1727	29	26	data	datum	NOUN
gs-1727	29	27	between	between	ADP
gs-1727	29	28	the	the	DET
gs-1727	29	29	two	two	NUM
gs-1727	29	30	groups	group	NOUN
gs-1727	29	31	.	.	PUNCT
gs-1727	30	1	methods	method	NOUN
gs-1727	30	2	this	this	DET
gs-1727	30	3	retrospective	retrospective	ADJ
gs-1727	30	4	study	study	NOUN
gs-1727	30	5	was	be	AUX
gs-1727	30	6	conducted	conduct	VERB
gs-1727	30	7	from	from	ADP
gs-1727	30	8	september	september	PROPN
gs-1727	30	9	2019	2019	NUM
gs-1727	30	10	to	to	ADP
gs-1727	30	11	december	december	PROPN
gs-1727	30	12	2022	2022	NUM
gs-1727	30	13	at	at	ADP
gs-1727	30	14	the	the	DET
gs-1727	30	15	center	center	NOUN
gs-1727	30	16	of	of	ADP
gs-1727	30	17	allergy	allergy	NOUN
gs-1727	30	18	and	and	CCONJ
gs-1727	30	19	immunology	immunology	NOUN
gs-1727	30	20	in	in	ADP
gs-1727	30	21	tbilisi	tbilisi	PROPN
gs-1727	30	22	,	,	PUNCT
gs-1727	30	23	georgia	georgia	PROPN
gs-1727	30	24	(	(	PUNCT
gs-1727	30	25	ga²len	ga²len	NOUN
gs-1727	30	26	urticaria	urticaria	NOUN
gs-1727	30	27	center	center	NOUN
gs-1727	30	28	of	of	ADP
gs-1727	30	29	reference	reference	NOUN
gs-1727	30	30	and	and	CCONJ
gs-1727	30	31	excellence	excellence	NOUN
gs-1727	30	32	)	)	PUNCT
gs-1727	30	33	.	.	PUNCT
gs-1727	31	1	thirty	thirty	NUM
gs-1727	31	2	-	-	PUNCT
gs-1727	31	3	nine	nine	NUM
gs-1727	31	4	adults	adult	NOUN
gs-1727	31	5	and	and	CCONJ
gs-1727	31	6	adolescents	adolescent	NOUN
gs-1727	31	7	(	(	PUNCT
gs-1727	31	8	≥	≥	NOUN
gs-1727	31	9	12	12	NUM
gs-1727	31	10	years	year	NOUN
gs-1727	31	11	old	old	ADJ
gs-1727	31	12	)	)	PUNCT
gs-1727	31	13	with	with	ADP
gs-1727	31	14	a	a	DET
gs-1727	31	15	diagnosis	diagnosis	NOUN
gs-1727	31	16	of	of	ADP
gs-1727	31	17	csu	csu	PROPN
gs-1727	31	18	,	,	PUNCT
gs-1727	31	19	confirmed	confirm	VERB
gs-1727	31	20	by	by	ADP
gs-1727	31	21	an	an	DET
gs-1727	31	22	allergologist	allergologist	NOUN
gs-1727	31	23	according	accord	VERB
gs-1727	31	24	to	to	ADP
gs-1727	31	25	the	the	DET
gs-1727	31	26	international	international	PROPN
gs-1727	31	27	guideline1	guideline1	PROPN
gs-1727	31	28	,	,	PUNCT
gs-1727	31	29	were	be	AUX
gs-1727	31	30	included	include	VERB
gs-1727	31	31	.	.	PUNCT
gs-1727	32	1	the	the	DET
gs-1727	32	2	study	study	NOUN
gs-1727	32	3	included	include	VERB
gs-1727	32	4	patients	patient	NOUN
gs-1727	32	5	with	with	ADP
gs-1727	32	6	high	high	ADJ
gs-1727	32	7	disease	disease	NOUN
gs-1727	32	8	activity	activity	NOUN
gs-1727	32	9	despite	despite	SCONJ
gs-1727	32	10	using	use	VERB
gs-1727	32	11	a	a	DET
gs-1727	32	12	fourfold	fourfold	ADJ
gs-1727	32	13	dose	dose	NOUN
gs-1727	32	14	of	of	ADP
gs-1727	32	15	non	non	ADJ
gs-1727	32	16	-	-	ADJ
gs-1727	32	17	sedating	sedating	ADJ
gs-1727	32	18	antihistamines	antihistamine	NOUN
gs-1727	32	19	.	.	PUNCT
gs-1727	33	1	according	accord	VERB
gs-1727	33	2	to	to	ADP
gs-1727	33	3	international	international	ADJ
gs-1727	33	4	guidelines	guideline	NOUN
gs-1727	33	5	,	,	PUNCT
gs-1727	33	6	these	these	DET
gs-1727	33	7	patients	patient	NOUN
gs-1727	33	8	have	have	AUX
gs-1727	33	9	been	be	AUX
gs-1727	33	10	prescribed	prescribe	VERB
gs-1727	33	11	omalizumab	omalizumab	NOUN
gs-1727	33	12	at	at	ADP
gs-1727	33	13	intervals	interval	NOUN
gs-1727	33	14	of	of	ADP
gs-1727	33	15	4	4	NUM
gs-1727	33	16	weeks	week	NOUN
gs-1727	33	17	for	for	ADP
gs-1727	33	18	at	at	ADV
gs-1727	33	19	least	least	ADV
gs-1727	33	20	three	three	NUM
gs-1727	33	21	months	month	NOUN
gs-1727	33	22	.	.	PUNCT
gs-1727	34	1	georgian	georgian	ADJ
gs-1727	34	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-1727	34	3	მეცნიერები	მეცნიერები	NOUN
gs-1727	34	4	ტ.	ტ.	VERB
gs-1727	34	5	5	5	NUM
gs-1727	34	6	n	n	PRON
gs-1727	34	7	2	2	NUM
gs-1727	34	8	,	,	PUNCT
gs-1727	34	9	2023	2023	NUM
gs-1727	34	10	111	111	NUM
gs-1727	34	11	patients	patient	NOUN
gs-1727	34	12	were	be	AUX
gs-1727	34	13	divided	divide	VERB
gs-1727	34	14	into	into	ADP
gs-1727	34	15	two	two	NUM
gs-1727	34	16	groups	group	NOUN
gs-1727	34	17	according	accord	VERB
gs-1727	34	18	to	to	ADP
gs-1727	34	19	autoimmunity	autoimmunity	NOUN
gs-1727	34	20	.	.	PUNCT
gs-1727	35	1	total	total	ADJ
gs-1727	35	2	ige	ige	PROPN
gs-1727	35	3	and	and	CCONJ
gs-1727	35	4	ana	ana	PROPN
gs-1727	35	5	antibodies	antibody	NOUN
gs-1727	35	6	were	be	AUX
gs-1727	35	7	taken	take	VERB
gs-1727	35	8	as	as	ADP
gs-1727	35	9	markers	marker	NOUN
gs-1727	35	10	of	of	ADP
gs-1727	35	11	autoimmunity	autoimmunity	NOUN
gs-1727	35	12	.	.	PUNCT
gs-1727	36	1	namely	namely	ADV
gs-1727	36	2	,	,	PUNCT
gs-1727	36	3	the	the	DET
gs-1727	36	4	first	first	ADJ
gs-1727	36	5	group	group	NOUN
gs-1727	36	6	is	be	AUX
gs-1727	36	7	type	type	NOUN
gs-1727	36	8	i	i	PRON
gs-1727	36	9	autoimmunity	autoimmunity	NOUN
gs-1727	36	10	with	with	ADP
gs-1727	36	11	high	high	ADJ
gs-1727	36	12	total	total	ADJ
gs-1727	36	13	ige	ige	NOUN
gs-1727	36	14	(	(	PUNCT
gs-1727	36	15	>	>	X
gs-1727	36	16	43	43	NUM
gs-1727	36	17	ku	ku	PROPN
gs-1727	36	18	/	/	SYM
gs-1727	36	19	l	l	NOUN
gs-1727	36	20	)	)	PUNCT
gs-1727	36	21	and	and	CCONJ
gs-1727	36	22	negative	negative	ADJ
gs-1727	36	23	ana	ana	PROPN
gs-1727	36	24	,	,	PUNCT
gs-1727	36	25	and	and	CCONJ
gs-1727	36	26	type	type	NOUN
gs-1727	36	27	iib	iib	NOUN
gs-1727	36	28	autoimmunity	autoimmunity	NOUN
gs-1727	36	29	with	with	ADP
gs-1727	36	30	low	low	ADJ
gs-1727	36	31	total	total	ADJ
gs-1727	36	32	ige	ige	NOUN
gs-1727	36	33	(	(	PUNCT
gs-1727	36	34	<	<	X
gs-1727	36	35	43	43	NUM
gs-1727	36	36	ku	ku	PROPN
gs-1727	36	37	/	/	SYM
gs-1727	36	38	l	l	NOUN
gs-1727	36	39	)	)	PUNCT
gs-1727	36	40	and	and	CCONJ
gs-1727	36	41	positive	positive	ADJ
gs-1727	36	42	ana	ana	PROPN
gs-1727	36	43	.	.	PUNCT
gs-1727	37	1	disease	disease	NOUN
gs-1727	37	2	activity	activity	NOUN
gs-1727	37	3	was	be	AUX
gs-1727	37	4	determined	determine	VERB
gs-1727	37	5	using	use	VERB
gs-1727	37	6	the	the	DET
gs-1727	37	7	urticaria	urticaria	NOUN
gs-1727	37	8	activity	activity	NOUN
gs-1727	37	9	score	score	NOUN
gs-1727	37	10	(	(	PUNCT
gs-1727	37	11	uas	uas	PROPN
gs-1727	37	12	)	)	PUNCT
gs-1727	37	13	,	,	PUNCT
gs-1727	37	14	which	which	PRON
gs-1727	37	15	was	be	AUX
gs-1727	37	16	calculated	calculate	VERB
gs-1727	37	17	as	as	ADP
gs-1727	37	18	the	the	DET
gs-1727	37	19	sum	sum	NOUN
gs-1727	37	20	of	of	ADP
gs-1727	37	21	the	the	DET
gs-1727	37	22	itch	itch	NOUN
gs-1727	37	23	(	(	PUNCT
gs-1727	37	24	no	no	NOUN
gs-1727	37	25	=	=	NOUN
gs-1727	37	26	0	0	NUM
gs-1727	37	27	,	,	PUNCT
gs-1727	37	28	mild	mild	ADJ
gs-1727	37	29	=	=	SYM
gs-1727	37	30	1	1	NUM
gs-1727	37	31	,	,	PUNCT
gs-1727	37	32	moderate	moderate	ADJ
gs-1727	37	33	=	=	SYM
gs-1727	37	34	2	2	NUM
gs-1727	37	35	,	,	PUNCT
gs-1727	37	36	intense	intense	ADJ
gs-1727	37	37	=	=	SYM
gs-1727	37	38	3	3	NUM
gs-1727	37	39	)	)	PUNCT
gs-1727	37	40	and	and	CCONJ
gs-1727	37	41	the	the	DET
gs-1727	37	42	wheal	wheal	ADJ
gs-1727	37	43	score	score	NOUN
gs-1727	37	44	(	(	PUNCT
gs-1727	37	45	no	no	DET
gs-1727	37	46	wheals	wheal	NOUN
gs-1727	37	47	=	=	SYM
gs-1727	37	48	0	0	NUM
gs-1727	37	49	,	,	PUNCT
gs-1727	37	50	<	<	X
gs-1727	37	51	20	20	NUM
gs-1727	37	52	wheals/24	wheals/24	NOUN
gs-1727	37	53	hr	hr	NOUN
gs-1727	37	54	=	=	SYM
gs-1727	37	55	1	1	NUM
gs-1727	37	56	,	,	PUNCT
gs-1727	37	57	20–50	20–50	NUM
gs-1727	37	58	wheals/24	wheals/24	VERB
gs-1727	37	59	hr	hr	NOUN
gs-1727	37	60	=	=	SYM
gs-1727	37	61	2	2	NUM
gs-1727	37	62	,	,	PUNCT
gs-1727	37	63	>	>	X
gs-1727	37	64	50	50	NUM
gs-1727	37	65	wheals/24	wheals/24	NOUN
gs-1727	37	66	hr	hr	NOUN
gs-1727	37	67	=	=	NOUN
gs-1727	37	68	3	3	X
gs-1727	37	69	)	)	PUNCT
gs-1727	37	70	for	for	ADP
gs-1727	37	71	seven	seven	NUM
gs-1727	37	72	consecutive	consecutive	ADJ
gs-1727	37	73	days	day	NOUN
gs-1727	37	74	(	(	PUNCT
gs-1727	37	75	uas7	uas7	PROPN
gs-1727	37	76	,	,	PUNCT
gs-1727	37	77	minimum	minimum	NOUN
gs-1727	37	78	=	=	SYM
gs-1727	37	79	0	0	NUM
gs-1727	37	80	,	,	PUNCT
gs-1727	37	81	maximum	maximum	ADJ
gs-1727	37	82	=	=	NOUN
gs-1727	37	83	42	42	NUM
gs-1727	37	84	)	)	PUNCT
gs-1727	37	85	.	.	PUNCT
gs-1727	38	1	response	response	NOUN
gs-1727	38	2	to	to	ADP
gs-1727	38	3	omalizumab	omalizumab	NOUN
gs-1727	38	4	was	be	AUX
gs-1727	38	5	assessed	assess	VERB
gs-1727	38	6	as	as	ADP
gs-1727	38	7	non	non	NOUN
gs-1727	38	8	-	-	NOUN
gs-1727	38	9	responders	responder	NOUN
gs-1727	38	10	(	(	PUNCT
gs-1727	38	11	a	a	DET
gs-1727	38	12	reduction	reduction	NOUN
gs-1727	38	13	in	in	ADP
gs-1727	38	14	uas7	uas7	NOUN
gs-1727	38	15	of	of	ADP
gs-1727	38	16	less	less	ADJ
gs-1727	38	17	than	than	ADP
gs-1727	38	18	30	30	NUM
gs-1727	38	19	%	%	NOUN
gs-1727	38	20	)	)	PUNCT
gs-1727	38	21	,	,	PUNCT
gs-1727	38	22	partial	partial	ADJ
gs-1727	38	23	responders	responder	NOUN
gs-1727	38	24	(	(	PUNCT
gs-1727	38	25	a	a	DET
gs-1727	38	26	reduction	reduction	NOUN
gs-1727	38	27	in	in	ADP
gs-1727	38	28	uas7	uas7	NOUN
gs-1727	38	29	of	of	ADP
gs-1727	38	30	30	30	NUM
gs-1727	38	31	%	%	NOUN
gs-1727	38	32	to	to	PART
gs-1727	38	33	89	89	NUM
gs-1727	38	34	%	%	NOUN
gs-1727	38	35	)	)	PUNCT
gs-1727	38	36	,	,	PUNCT
gs-1727	38	37	and	and	CCONJ
gs-1727	38	38	complete	complete	ADJ
gs-1727	38	39	responders	responder	NOUN
gs-1727	38	40	(	(	PUNCT
gs-1727	38	41	a	a	DET
gs-1727	38	42	reduction	reduction	NOUN
gs-1727	38	43	of	of	ADP
gs-1727	38	44	90	90	NUM
gs-1727	38	45	%	%	NOUN
gs-1727	38	46	or	or	CCONJ
gs-1727	38	47	more	more	ADJ
gs-1727	38	48	from	from	ADP
gs-1727	38	49	baseline	baseline	NOUN
gs-1727	38	50	in	in	ADP
gs-1727	38	51	uas7	uas7	NOUN
gs-1727	38	52	)	)	PUNCT
gs-1727	38	53	,	,	PUNCT
gs-1727	38	54	respectively	respectively	ADV
gs-1727	38	55	.	.	PUNCT
gs-1727	39	1	according	accord	VERB
gs-1727	39	2	to	to	ADP
gs-1727	39	3	the	the	DET
gs-1727	39	4	manufacturer	manufacturer	NOUN
gs-1727	39	5	's	's	PART
gs-1727	39	6	instructions	instruction	NOUN
gs-1727	39	7	,	,	PUNCT
gs-1727	39	8	total	total	ADJ
gs-1727	39	9	ige	ige	PROPN
gs-1727	39	10	levels	level	NOUN
gs-1727	39	11	were	be	AUX
gs-1727	39	12	measured	measure	VERB
gs-1727	39	13	using	use	VERB
gs-1727	39	14	the	the	DET
gs-1727	39	15	immunocap	immunocap	NOUN
gs-1727	39	16	system	system	NOUN
gs-1727	39	17	(	(	PUNCT
gs-1727	39	18	thermo	thermo	NOUN
gs-1727	39	19	-	-	PUNCT
gs-1727	39	20	fisher	fisher	PROPN
gs-1727	39	21	,	,	PUNCT
gs-1727	39	22	uppsala	uppsala	PROPN
gs-1727	39	23	,	,	PUNCT
gs-1727	39	24	sweden	sweden	PROPN
gs-1727	39	25	)	)	PUNCT
gs-1727	39	26	.	.	PUNCT
gs-1727	40	1	ana	ana	PROPN
gs-1727	40	2	was	be	AUX
gs-1727	40	3	detected	detect	VERB
gs-1727	40	4	using	use	VERB
gs-1727	40	5	hep-2	hep-2	PUNCT
gs-1727	40	6	cells	cell	NOUN
gs-1727	40	7	and	and	CCONJ
gs-1727	40	8	an	an	DET
gs-1727	40	9	indirect	indirect	ADJ
gs-1727	40	10	fluorescent	fluorescent	ADJ
gs-1727	40	11	antibody	antibody	NOUN
gs-1727	40	12	technique	technique	NOUN
gs-1727	40	13	.	.	PUNCT
gs-1727	41	1	the	the	DET
gs-1727	41	2	result	result	NOUN
gs-1727	41	3	would	would	AUX
gs-1727	41	4	be	be	AUX
gs-1727	41	5	reported	report	VERB
gs-1727	41	6	as	as	ADP
gs-1727	41	7	a	a	DET
gs-1727	41	8	titer	titer	NOUN
gs-1727	41	9	.	.	PUNCT
gs-1727	42	1	the	the	DET
gs-1727	42	2	cut	cut	VERB
gs-1727	42	3	-	-	PUNCT
gs-1727	42	4	off	off	ADP
gs-1727	42	5	value	value	NOUN
gs-1727	42	6	to	to	PART
gs-1727	42	7	define	define	VERB
gs-1727	42	8	positive	positive	ADJ
gs-1727	42	9	ana	ana	NOUN
gs-1727	42	10	was	be	AUX
gs-1727	42	11	1:80	1:80	NUM
gs-1727	42	12	.	.	PUNCT
gs-1727	43	1	thyroid	thyroid	PROPN
gs-1727	43	2	microsomal	microsomal	ADJ
gs-1727	43	3	antibodies	antibody	NOUN
gs-1727	43	4	were	be	AUX
gs-1727	43	5	detected	detect	VERB
gs-1727	43	6	by	by	ADP
gs-1727	43	7	radioimmunoassay	radioimmunoassay	PROPN
gs-1727	43	8	(	(	PUNCT
gs-1727	43	9	cut	cut	VERB
gs-1727	43	10	off	off	ADP
gs-1727	43	11	>	>	X
gs-1727	43	12	34	34	NUM
gs-1727	43	13	ku	ku	PROPN
gs-1727	43	14	/	/	SYM
gs-1727	43	15	l	l	NOUN
gs-1727	43	16	)	)	PUNCT
gs-1727	43	17	.	.	PUNCT
gs-1727	44	1	serum	serum	PROPN
gs-1727	44	2	crp	crp	PROPN
gs-1727	44	3	concentrations	concentration	NOUN
gs-1727	44	4	were	be	AUX
gs-1727	44	5	measured	measure	VERB
gs-1727	44	6	by	by	ADP
gs-1727	44	7	elisa	elisa	NOUN
gs-1727	44	8	using	use	VERB
gs-1727	44	9	commercially	commercially	ADV
gs-1727	44	10	available	available	ADJ
gs-1727	44	11	reagents	reagent	NOUN
gs-1727	44	12	(	(	PUNCT
gs-1727	44	13	reference	reference	NOUN
gs-1727	44	14	range	range	VERB
gs-1727	44	15	<	<	X
gs-1727	44	16	6.0	6.0	NUM
gs-1727	44	17	mg	mg	NUM
gs-1727	44	18	/	/	SYM
gs-1727	44	19	l	l	NOUN
gs-1727	44	20	)	)	PUNCT
gs-1727	44	21	.	.	PUNCT
gs-1727	45	1	h.	h.	PROPN
gs-1727	45	2	pylori	pylori	NOUN
gs-1727	45	3	was	be	AUX
gs-1727	45	4	detected	detect	VERB
gs-1727	45	5	by	by	ADP
gs-1727	45	6	a	a	DET
gs-1727	45	7	stool	stool	NOUN
gs-1727	45	8	antigen	antigen	ADJ
gs-1727	45	9	test	test	NOUN
gs-1727	45	10	.	.	PUNCT
gs-1727	46	1	statistical	statistical	ADJ
gs-1727	46	2	analysis	analysis	NOUN
gs-1727	46	3	:	:	PUNCT
gs-1727	46	4	differences	difference	NOUN
gs-1727	46	5	in	in	ADP
gs-1727	46	6	continuous	continuous	ADJ
gs-1727	46	7	variables	variable	NOUN
gs-1727	46	8	between	between	ADP
gs-1727	46	9	test	test	NOUN
gs-1727	46	10	samples	sample	NOUN
gs-1727	46	11	were	be	AUX
gs-1727	46	12	analyzed	analyze	VERB
gs-1727	46	13	using	use	VERB
gs-1727	46	14	a	a	DET
gs-1727	46	15	ttest	ttest	NOUN
gs-1727	46	16	for	for	ADP
gs-1727	46	17	independent	independent	ADJ
gs-1727	46	18	samples	sample	NOUN
gs-1727	46	19	and	and	CCONJ
gs-1727	46	20	the	the	DET
gs-1727	46	21	mann	mann	PROPN
gs-1727	46	22	-	-	PUNCT
gs-1727	46	23	whitney	whitney	PROPN
gs-1727	46	24	u	u	PROPN
gs-1727	46	25	test	test	NOUN
gs-1727	46	26	.	.	PUNCT
gs-1727	47	1	the	the	DET
gs-1727	47	2	chi	chi	ADJ
gs-1727	47	3	-	-	PUNCT
gs-1727	47	4	square	square	ADJ
gs-1727	47	5	test	test	NOUN
gs-1727	47	6	was	be	AUX
gs-1727	47	7	used	use	VERB
gs-1727	47	8	to	to	PART
gs-1727	47	9	see	see	VERB
gs-1727	47	10	differences	difference	NOUN
gs-1727	47	11	in	in	ADP
gs-1727	47	12	categorical	categorical	ADJ
gs-1727	47	13	variables	variable	NOUN
gs-1727	47	14	.	.	PUNCT
gs-1727	48	1	normally	normally	ADV
gs-1727	48	2	distributed	distribute	VERB
gs-1727	48	3	data	datum	NOUN
gs-1727	48	4	are	be	AUX
gs-1727	48	5	presented	present	VERB
gs-1727	48	6	as	as	ADP
gs-1727	48	7	mean	mean	NOUN
gs-1727	48	8	±	±	NUM
gs-1727	48	9	sd	sd	NOUN
gs-1727	48	10	,	,	PUNCT
gs-1727	48	11	and	and	CCONJ
gs-1727	48	12	nonnormally	nonnormally	ADV
gs-1727	48	13	distributed	distribute	VERB
gs-1727	48	14	data	datum	NOUN
gs-1727	48	15	are	be	AUX
gs-1727	48	16	expressed	express	VERB
gs-1727	48	17	as	as	ADP
gs-1727	48	18	a	a	DET
gs-1727	48	19	median	median	NOUN
gs-1727	48	20	.	.	PUNCT
gs-1727	49	1	date	date	NOUN
gs-1727	49	2	were	be	AUX
gs-1727	49	3	analyzed	analyze	VERB
gs-1727	49	4	using	use	VERB
gs-1727	49	5	spss	spss	PROPN
gs-1727	49	6	software	software	NOUN
gs-1727	49	7	version	version	NOUN
gs-1727	49	8	22.0	22.0	NUM
gs-1727	49	9	(	(	PUNCT
gs-1727	49	10	ibm	ibm	PROPN
gs-1727	49	11	corporation	corporation	NOUN
gs-1727	49	12	,	,	PUNCT
gs-1727	49	13	new	new	PROPN
gs-1727	49	14	york	york	PROPN
gs-1727	49	15	,	,	PUNCT
gs-1727	49	16	usa	usa	PROPN
gs-1727	49	17	)	)	PUNCT
gs-1727	49	18	.	.	PUNCT
gs-1727	50	1	statistical	statistical	ADJ
gs-1727	50	2	significance	significance	NOUN
gs-1727	50	3	was	be	AUX
gs-1727	50	4	defined	define	VERB
gs-1727	50	5	as	as	ADP
gs-1727	50	6	p	p	X
gs-1727	50	7	 	 	SPACE
gs-1727	50	8	<	<	X
gs-1727	50	9	 	 	SPACE
gs-1727	50	10	0.05	0.05	NUM
gs-1727	50	11	.	.	PUNCT
gs-1727	51	1	results	result	NOUN
gs-1727	51	2	of	of	ADP
gs-1727	51	3	the	the	DET
gs-1727	51	4	39	39	NUM
gs-1727	51	5	patients	patient	NOUN
gs-1727	51	6	in	in	ADP
gs-1727	51	7	this	this	DET
gs-1727	51	8	study	study	NOUN
gs-1727	51	9	,	,	PUNCT
gs-1727	51	10	95	95	NUM
gs-1727	51	11	%	%	NOUN
gs-1727	51	12	(	(	PUNCT
gs-1727	51	13	n=37	n=37	NOUN
gs-1727	51	14	)	)	PUNCT
gs-1727	51	15	were	be	AUX
gs-1727	51	16	females	female	NOUN
gs-1727	51	17	,	,	PUNCT
gs-1727	51	18	and	and	CCONJ
gs-1727	51	19	5	5	NUM
gs-1727	51	20	%	%	NOUN
gs-1727	51	21	(	(	PUNCT
gs-1727	51	22	n=2	n=2	ADV
gs-1727	51	23	)	)	PUNCT
gs-1727	51	24	were	be	AUX
gs-1727	51	25	males	male	NOUN
gs-1727	51	26	.	.	PUNCT
gs-1727	52	1	average	average	ADJ
gs-1727	52	2	age	age	NOUN
gs-1727	52	3	35.82	35.82	NUM
gs-1727	52	4	years	year	NOUN
gs-1727	52	5	(	(	PUNCT
gs-1727	52	6	range	range	NOUN
gs-1727	52	7	12	12	NUM
gs-1727	52	8	-	-	SYM
gs-1727	52	9	71	71	NUM
gs-1727	52	10	)	)	PUNCT
gs-1727	52	11	.	.	PUNCT
gs-1727	53	1	the	the	DET
gs-1727	53	2	results	result	NOUN
gs-1727	53	3	indicate	indicate	VERB
gs-1727	53	4	that	that	DET
gs-1727	53	5	type	type	NOUN
gs-1727	53	6	i	i	PRON
gs-1727	53	7	autoimmunity	autoimmunity	NOUN
gs-1727	53	8	had	have	VERB
gs-1727	53	9	a	a	DET
gs-1727	53	10	higher	high	ADJ
gs-1727	53	11	percentage	percentage	NOUN
gs-1727	53	12	of	of	ADP
gs-1727	53	13	complete	complete	ADJ
gs-1727	53	14	responders	responder	NOUN
gs-1727	53	15	(	(	PUNCT
gs-1727	53	16	cr	cr	NOUN
gs-1727	53	17	)	)	PUNCT
gs-1727	53	18	than	than	ADP
gs-1727	53	19	type	type	NOUN
gs-1727	53	20	iib	iib	NOUN
gs-1727	53	21	(	(	PUNCT
gs-1727	53	22	55.5	55.5	NUM
gs-1727	53	23	%	%	NOUN
gs-1727	53	24	vs.	vs.	ADP
gs-1727	53	25	18.3	18.3	NUM
gs-1727	53	26	%	%	NOUN
gs-1727	53	27	)	)	PUNCT
gs-1727	53	28	.	.	PUNCT
gs-1727	54	1	non	non	ADJ
gs-1727	54	2	-	-	ADJ
gs-1727	54	3	responder	responder	ADJ
gs-1727	54	4	(	(	PUNCT
gs-1727	54	5	nr	nr	NOUN
gs-1727	54	6	)	)	PUNCT
gs-1727	54	7	rates	rate	NOUN
gs-1727	54	8	were	be	AUX
gs-1727	54	9	higher	high	ADJ
gs-1727	54	10	in	in	ADP
gs-1727	54	11	type	type	NOUN
gs-1727	54	12	iib	iib	NOUN
gs-1727	54	13	than	than	ADP
gs-1727	54	14	in	in	ADP
gs-1727	54	15	type	type	NOUN
gs-1727	54	16	i	i	NOUN
gs-1727	54	17	(	(	PUNCT
gs-1727	54	18	72.7	72.7	NUM
gs-1727	54	19	%	%	NOUN
gs-1727	54	20	vs.	vs.	ADP
gs-1727	54	21	18.5	18.5	NUM
gs-1727	54	22	%	%	NOUN
gs-1727	54	23	)	)	PUNCT
gs-1727	54	24	.	.	PUNCT
gs-1727	55	1	the	the	DET
gs-1727	55	2	median	median	ADJ
gs-1727	55	3	total	total	ADJ
gs-1727	55	4	ige	ige	PROPN
gs-1727	55	5	levels	level	NOUN
gs-1727	55	6	were	be	AUX
gs-1727	55	7	significantly	significantly	ADV
gs-1727	55	8	higher	high	ADJ
gs-1727	55	9	in	in	ADP
gs-1727	55	10	type	type	NOUN
gs-1727	55	11	i	i	PRON
gs-1727	55	12	than	than	ADP
gs-1727	55	13	in	in	ADP
gs-1727	55	14	type	type	NOUN
gs-1727	55	15	iib	iib	NOUN
gs-1727	55	16	(	(	PUNCT
gs-1727	55	17	138	138	NUM
gs-1727	55	18	vs.	vs.	ADP
gs-1727	55	19	23.95	23.95	NUM
gs-1727	55	20	ku	ku	PROPN
gs-1727	55	21	/	/	SYM
gs-1727	55	22	i	i	PROPN
gs-1727	55	23	)	)	PUNCT
gs-1727	55	24	.	.	PUNCT
gs-1727	56	1	the	the	DET
gs-1727	56	2	median	median	ADJ
gs-1727	56	3	duration	duration	NOUN
gs-1727	56	4	of	of	ADP
gs-1727	56	5	the	the	DET
gs-1727	56	6	disease	disease	NOUN
gs-1727	56	7	was	be	AUX
gs-1727	56	8	markedly	markedly	ADV
gs-1727	56	9	shorter	short	ADJ
gs-1727	56	10	in	in	ADP
gs-1727	56	11	type	type	NOUN
gs-1727	56	12	i	i	PRON
gs-1727	56	13	than	than	ADP
gs-1727	56	14	in	in	ADP
gs-1727	56	15	type	type	NOUN
gs-1727	56	16	iib	iib	NOUN
gs-1727	56	17	(	(	PUNCT
gs-1727	56	18	9	9	NUM
gs-1727	56	19	vs.	vs.	ADP
gs-1727	56	20	27	27	NUM
gs-1727	56	21	months	month	NOUN
gs-1727	56	22	)	)	PUNCT
gs-1727	56	23	.	.	PUNCT
gs-1727	57	1	the	the	DET
gs-1727	57	2	study	study	NOUN
gs-1727	57	3	did	do	AUX
gs-1727	57	4	not	not	PART
gs-1727	57	5	find	find	VERB
gs-1727	57	6	significant	significant	ADJ
gs-1727	57	7	differences	difference	NOUN
gs-1727	57	8	between	between	ADP
gs-1727	57	9	the	the	DET
gs-1727	57	10	two	two	NUM
gs-1727	57	11	groups	group	NOUN
gs-1727	57	12	regarding	regard	VERB
gs-1727	57	13	age	age	NOUN
gs-1727	57	14	,	,	PUNCT
gs-1727	57	15	angioedema	angioedema	VERB
gs-1727	57	16	,	,	PUNCT
gs-1727	57	17	crp	crp	PROPN
gs-1727	57	18	levels	level	NOUN
gs-1727	57	19	,	,	PUNCT
gs-1727	57	20	h.	h.	PROPN
gs-1727	57	21	pylori	pylori	NOUN
gs-1727	57	22	infection	infection	NOUN
gs-1727	57	23	rates	rate	NOUN
gs-1727	57	24	,	,	PUNCT
gs-1727	57	25	anti	anti	ADJ
gs-1727	57	26	-	-	ADJ
gs-1727	57	27	tpo	tpo	ADJ
gs-1727	57	28	igg	igg	PROPN
gs-1727	57	29	levels	levels	PROPN
gs-1727	57	30	,	,	PUNCT
gs-1727	57	31	eosinopenia	eosinopenia	NOUN
gs-1727	57	32	,	,	PUNCT
gs-1727	57	33	and	and	CCONJ
gs-1727	57	34	basopenia	basopenia	NOUN
gs-1727	57	35	.	.	PUNCT
gs-1727	58	1	all	all	DET
gs-1727	58	2	data	datum	NOUN
gs-1727	58	3	are	be	AUX
gs-1727	58	4	collected	collect	VERB
gs-1727	58	5	in	in	ADP
gs-1727	58	6	table	table	NOUN
gs-1727	58	7	1	1	NUM
gs-1727	58	8	.	.	PUNCT
gs-1727	59	1	georgian	georgian	ADJ
gs-1727	59	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-1727	59	3	მეცნიერები	მეცნიერები	NOUN
gs-1727	59	4	ტ.	ტ.	VERB
gs-1727	59	5	5	5	NUM
gs-1727	59	6	n	n	PRON
gs-1727	59	7	2	2	NUM
gs-1727	59	8	,	,	PUNCT
gs-1727	59	9	2023	2023	NUM
gs-1727	59	10	112	112	NUM
gs-1727	59	11	table	table	NOUN
gs-1727	59	12	1	1	NUM
gs-1727	59	13	comparison	comparison	NOUN
gs-1727	59	14	between	between	ADP
gs-1727	59	15	the	the	DET
gs-1727	59	16	study	study	NOUN
gs-1727	59	17	populations	population	NOUN
gs-1727	59	18	'	'	PART
gs-1727	59	19	baseline	baseline	ADJ
gs-1727	59	20	clinical	clinical	ADJ
gs-1727	59	21	and	and	CCONJ
gs-1727	59	22	serological	serological	ADJ
gs-1727	59	23	characteristics	characteristic	NOUN
gs-1727	59	24	.	.	PUNCT
gs-1727	60	1	group1	group1	PROPN
gs-1727	60	2	type	type	NOUN
gs-1727	60	3	i	i	PRON
gs-1727	60	4	autoimmunity	autoimmunity	NOUN
gs-1727	60	5	(	(	PUNCT
gs-1727	60	6	total	total	ADJ
gs-1727	60	7	ige	ige	PROPN
gs-1727	60	8	high	high	PROPN
gs-1727	60	9	>	>	X
gs-1727	60	10	43	43	NUM
gs-1727	60	11	,	,	PUNCT
gs-1727	60	12	ana	ana	PROPN
gs-1727	60	13	-	-	PUNCT
gs-1727	60	14	)	)	PUNCT
gs-1727	60	15	n=28	n=28	NOUN
gs-1727	60	16	group	group	NOUN
gs-1727	60	17	2	2	NUM
gs-1727	60	18	type	type	NOUN
gs-1727	60	19	iib	iib	NOUN
gs-1727	60	20	autoimmunity	autoimmunity	NOUN
gs-1727	60	21	(	(	PUNCT
gs-1727	60	22	total	total	ADJ
gs-1727	60	23	ige	ige	PROPN
gs-1727	60	24	high	high	ADJ
gs-1727	60	25	<	<	X
gs-1727	60	26	43	43	NUM
gs-1727	60	27	,	,	PUNCT
gs-1727	60	28	ana	ana	PROPN
gs-1727	60	29	+	+	PROPN
gs-1727	60	30	)	)	PUNCT
gs-1727	60	31	n=11	n=11	PRON
gs-1727	60	32	p	p	ADJ
gs-1727	60	33	-	-	PUNCT
gs-1727	60	34	value	value	NOUN
gs-1727	60	35	gender	gender	NOUN
gs-1727	60	36	(	(	PUNCT
gs-1727	60	37	female	female	NOUN
gs-1727	60	38	)	)	PUNCT
gs-1727	60	39	92	92	NUM
gs-1727	60	40	%	%	NOUN
gs-1727	60	41	100	100	NUM
gs-1727	60	42	%	%	NOUN
gs-1727	60	43	age	age	NOUN
gs-1727	60	44	(	(	PUNCT
gs-1727	60	45	years	year	NOUN
gs-1727	60	46	)	)	PUNCT
gs-1727	60	47	(	(	PUNCT
gs-1727	60	48	mean	mean	VERB
gs-1727	60	49	±	±	NUM
gs-1727	60	50	sd	sd	NOUN
gs-1727	60	51	,	,	PUNCT
gs-1727	60	52	range	range	NOUN
gs-1727	60	53	)	)	PUNCT
gs-1727	60	54	34.63	34.63	NUM
gs-1727	60	55	40.25	40.25	NUM
gs-1727	60	56	0.368	0.368	NUM
gs-1727	60	57	complete	complete	ADJ
gs-1727	60	58	responders	responder	NOUN
gs-1727	60	59	(	(	PUNCT
gs-1727	60	60	cr	cr	NOUN
gs-1727	60	61	)	)	PUNCT
gs-1727	60	62	55.5	55.5	NUM
gs-1727	60	63	%	%	NOUN
gs-1727	60	64	18.3	18.3	NUM
gs-1727	60	65	%	%	NOUN
gs-1727	60	66	0.004	0.004	NUM
gs-1727	60	67	*	*	NOUN
gs-1727	60	68	partial	partial	ADJ
gs-1727	60	69	responders	responder	NOUN
gs-1727	60	70	(	(	PUNCT
gs-1727	60	71	pr	pr	NOUN
gs-1727	60	72	)	)	PUNCT
gs-1727	60	73	26	26	NUM
gs-1727	60	74	%	%	NOUN
gs-1727	60	75	9	9	NUM
gs-1727	60	76	%	%	NOUN
gs-1727	60	77	0.758	0.758	NUM
gs-1727	60	78	non	non	ADJ
gs-1727	60	79	responders	responder	NOUN
gs-1727	60	80	(	(	PUNCT
gs-1727	60	81	nr	nr	NOUN
gs-1727	60	82	)	)	PUNCT
gs-1727	60	83	18.5	18.5	NUM
gs-1727	60	84	%	%	NOUN
gs-1727	60	85	72.7%%	72.7%%	NUM
gs-1727	60	86	0.012	0.012	NUM
gs-1727	60	87	*	*	NOUN
gs-1727	60	88	angioedema	angioedema	VERB
gs-1727	60	89	42	42	NUM
gs-1727	60	90	%	%	NOUN
gs-1727	60	91	60	60	NUM
gs-1727	60	92	%	%	NOUN
gs-1727	60	93	0.351	0.351	NUM
gs-1727	60	94	duration	duration	NOUN
gs-1727	60	95	of	of	ADP
gs-1727	60	96	diseases	disease	NOUN
gs-1727	60	97	(	(	PUNCT
gs-1727	60	98	month	month	NOUN
gs-1727	60	99	)	)	PUNCT
gs-1727	60	100	median	median	NOUN
gs-1727	60	101	9	9	NUM
gs-1727	60	102	27	27	NUM
gs-1727	60	103	0.019	0.019	NUM
gs-1727	60	104	*	*	PUNCT
gs-1727	60	105	total	total	ADJ
gs-1727	60	106	ige	ige	PROPN
gs-1727	60	107	ku	ku	PROPN
gs-1727	60	108	/	/	SYM
gs-1727	60	109	i	i	PROPN
gs-1727	60	110	(	(	PUNCT
gs-1727	60	111	median	median	PROPN
gs-1727	60	112	)	)	PUNCT
gs-1727	60	113	138	138	NUM
gs-1727	60	114	(	(	PUNCT
gs-1727	60	115	min	min	NOUN
gs-1727	60	116	-	-	ADJ
gs-1727	60	117	max	max	PROPN
gs-1727	60	118	8.6	8.6	NUM
gs-1727	60	119	-	-	SYM
gs-1727	60	120	1297	1297	NUM
gs-1727	60	121	)	)	PUNCT
gs-1727	60	122	23.95	23.95	NUM
gs-1727	60	123	(	(	PUNCT
gs-1727	60	124	min	min	NOUN
gs-1727	60	125	-	-	ADJ
gs-1727	60	126	max	max	NOUN
gs-1727	60	127	5.73	5.73	NUM
gs-1727	60	128	-	-	SYM
gs-1727	60	129	386	386	NUM
gs-1727	60	130	)	)	PUNCT
gs-1727	60	131	0.02	0.02	NUM
gs-1727	60	132	*	*	SYM
gs-1727	60	133	crp	crp	NOUN
gs-1727	60	134	24.57	24.57	NUM
gs-1727	60	135	+	+	NUM
gs-1727	60	136	42.96	42.96	NUM
gs-1727	60	137	22.71	22.71	NUM
gs-1727	60	138	+	+	NOUN
gs-1727	60	139	39.67	39.67	NUM
gs-1727	60	140	0.444	0.444	NUM
gs-1727	60	141	h.pylori	h.pylori	NOUN
gs-1727	60	142	+	+	CCONJ
gs-1727	60	143	32	32	NUM
gs-1727	60	144	%	%	NOUN
gs-1727	60	145	27	27	NUM
gs-1727	60	146	%	%	NOUN
gs-1727	60	147	0.085	0.085	NUM
gs-1727	60	148	anti	anti	ADJ
gs-1727	60	149	-	-	ADJ
gs-1727	60	150	tpo	tpo	ADJ
gs-1727	60	151	igg	igg	NOUN
gs-1727	60	152	+	+	PROPN
gs-1727	60	153	50	50	NUM
gs-1727	60	154	%	%	NOUN
gs-1727	60	155	36.6	36.6	NUM
gs-1727	60	156	%	%	NOUN
gs-1727	60	157	0.867	0.867	NUM
gs-1727	60	158	eosinopenia	eosinopenia	NOUN
gs-1727	60	159	(	(	PUNCT
gs-1727	60	160	<	<	X
gs-1727	60	161	0.05	0.05	NUM
gs-1727	60	162	×	×	NOUN
gs-1727	60	163	109	109	NUM
gs-1727	60	164	/	/	SYM
gs-1727	60	165	l	l	NOUN
gs-1727	60	166	)	)	PUNCT
gs-1727	60	167	0.24	0.24	NUM
gs-1727	60	168	0.21	0.21	NUM
gs-1727	60	169	0.847	0.847	NUM
gs-1727	60	170	basopenia	basopenia	NOUN
gs-1727	60	171	(	(	PUNCT
gs-1727	60	172	<	<	X
gs-1727	60	173	0.01	0.01	NUM
gs-1727	60	174	×	×	NOUN
gs-1727	60	175	109	109	NUM
gs-1727	60	176	/	/	SYM
gs-1727	60	177	l	l	NOUN
gs-1727	60	178	)	)	PUNCT
gs-1727	60	179	0.06	0.06	NUM
gs-1727	60	180	0.02	0.02	NUM
gs-1727	60	181	0.478	0.478	NUM
gs-1727	60	182	note	note	NOUN
gs-1727	60	183	:	:	PUNCT
gs-1727	60	184	crpc	crpc	ADJ
gs-1727	60	185	reactive	reactive	ADJ
gs-1727	60	186	protein	protein	NOUN
gs-1727	60	187	,	,	PUNCT
gs-1727	60	188	h.pylori	h.pylori	NOUN
gs-1727	60	189	–	–	PUNCT
gs-1727	60	190	helicobacter	helicobacter	NOUN
gs-1727	60	191	pylori	pylori	NOUN
gs-1727	60	192	,	,	PUNCT
gs-1727	60	193	igg	igg	PROPN
gs-1727	60	194	-	-	PUNCT
gs-1727	60	195	anti	anti	NOUN
gs-1727	60	196	-	-	ADJ
gs-1727	60	197	tpo	tpo	ADJ
gs-1727	60	198	anti	anti	ADJ
gs-1727	60	199	-	-	ADJ
gs-1727	60	200	thyroid	thyroid	ADJ
gs-1727	60	201	peroxidase	peroxidase	NOUN
gs-1727	60	202	immunoglobulin	immunoglobulin	PROPN
gs-1727	60	203	g.	g.	PROPN
gs-1727	60	204	*	*	PUNCT
gs-1727	60	205	statistically	statistically	ADV
gs-1727	60	206	significant	significant	ADJ
gs-1727	60	207	values	value	NOUN
gs-1727	60	208	are	be	AUX
gs-1727	60	209	shown	show	VERB
gs-1727	60	210	in	in	ADP
gs-1727	60	211	bold	bold	ADJ
gs-1727	60	212	georgian	georgian	ADJ
gs-1727	60	213	scientists/ქართველი	scientists/ქართველი	NOUN
gs-1727	60	214	მეცნიერები	მეცნიერები	NOUN
gs-1727	60	215	ტ.	ტ.	VERB
gs-1727	60	216	5	5	NUM
gs-1727	60	217	n	n	PRON
gs-1727	60	218	2	2	NUM
gs-1727	60	219	,	,	PUNCT
gs-1727	60	220	2023	2023	NUM
gs-1727	60	221	113	113	NUM
gs-1727	60	222	discussion	discussion	NOUN
gs-1727	60	223	the	the	DET
gs-1727	60	224	study	study	NOUN
gs-1727	60	225	aimed	aim	VERB
gs-1727	60	226	to	to	PART
gs-1727	60	227	evaluate	evaluate	VERB
gs-1727	60	228	the	the	DET
gs-1727	60	229	clinical	clinical	ADJ
gs-1727	60	230	response	response	NOUN
gs-1727	60	231	to	to	ADP
gs-1727	60	232	omalizumab	omalizumab	NOUN
gs-1727	60	233	in	in	ADP
gs-1727	60	234	patients	patient	NOUN
gs-1727	60	235	with	with	ADP
gs-1727	60	236	type	type	NOUN
gs-1727	60	237	1	1	NUM
gs-1727	60	238	and	and	CCONJ
gs-1727	60	239	type	type	NOUN
gs-1727	60	240	iib	iib	NOUN
gs-1727	60	241	autoimmunity	autoimmunity	NOUN
gs-1727	60	242	and	and	CCONJ
gs-1727	60	243	the	the	DET
gs-1727	60	244	difference	difference	NOUN
gs-1727	60	245	in	in	ADP
gs-1727	60	246	laboratory	laboratory	NOUN
gs-1727	60	247	data	datum	NOUN
gs-1727	60	248	.	.	PUNCT
gs-1727	61	1	patients	patient	NOUN
gs-1727	61	2	were	be	AUX
gs-1727	61	3	divided	divide	VERB
gs-1727	61	4	into	into	ADP
gs-1727	61	5	two	two	NUM
gs-1727	61	6	groups	group	NOUN
gs-1727	61	7	according	accord	VERB
gs-1727	61	8	to	to	ADP
gs-1727	61	9	autoimmunity	autoimmunity	NOUN
gs-1727	61	10	type	type	NOUN
gs-1727	61	11	i	i	PRON
gs-1727	61	12	autoimmunity	autoimmunity	NOUN
gs-1727	61	13	with	with	ADP
gs-1727	61	14	high	high	ADJ
gs-1727	61	15	total	total	ADJ
gs-1727	61	16	ige	ige	NOUN
gs-1727	61	17	(	(	PUNCT
gs-1727	61	18	(	(	PUNCT
gs-1727	61	19	>	>	X
gs-1727	61	20	43	43	NUM
gs-1727	61	21	ku	ku	PROPN
gs-1727	61	22	/	/	SYM
gs-1727	61	23	l	l	NOUN
gs-1727	61	24	)	)	PUNCT
gs-1727	61	25	and	and	CCONJ
gs-1727	61	26	negative	negative	ADJ
gs-1727	61	27	ana	ana	PROPN
gs-1727	61	28	and	and	CCONJ
gs-1727	61	29	type	type	NOUN
gs-1727	61	30	iib	iib	NOUN
gs-1727	61	31	autoimmunity	autoimmunity	NOUN
gs-1727	61	32	with	with	ADP
gs-1727	61	33	low	low	ADJ
gs-1727	61	34	total	total	ADJ
gs-1727	61	35	ige	ige	NOUN
gs-1727	61	36	(	(	PUNCT
gs-1727	61	37	<	<	X
gs-1727	61	38	43	43	NUM
gs-1727	61	39	ku	ku	PROPN
gs-1727	61	40	/	/	SYM
gs-1727	61	41	l	l	NOUN
gs-1727	61	42	)	)	PUNCT
gs-1727	61	43	and	and	CCONJ
gs-1727	61	44	positive	positive	ADJ
gs-1727	61	45	ana	ana	PROPN
gs-1727	61	46	.	.	PUNCT
gs-1727	62	1	the	the	DET
gs-1727	62	2	response	response	NOUN
gs-1727	62	3	to	to	ADP
gs-1727	62	4	omalizumab	omalizumab	NOUN
gs-1727	62	5	was	be	AUX
gs-1727	62	6	assessed	assess	VERB
gs-1727	62	7	as	as	ADP
gs-1727	62	8	non	non	NOUN
gs-1727	62	9	-	-	NOUN
gs-1727	62	10	responders	responder	NOUN
gs-1727	62	11	,	,	PUNCT
gs-1727	62	12	partial	partial	ADJ
gs-1727	62	13	responders	responder	NOUN
gs-1727	62	14	,	,	PUNCT
gs-1727	62	15	and	and	CCONJ
gs-1727	62	16	complete	complete	ADJ
gs-1727	62	17	responders	responder	NOUN
gs-1727	62	18	.	.	PUNCT
gs-1727	63	1	the	the	DET
gs-1727	63	2	results	result	NOUN
gs-1727	63	3	showed	show	VERB
gs-1727	63	4	that	that	DET
gs-1727	63	5	type	type	NOUN
gs-1727	63	6	i	i	PRON
gs-1727	63	7	autoimmunity	autoimmunity	NOUN
gs-1727	63	8	had	have	VERB
gs-1727	63	9	a	a	DET
gs-1727	63	10	higher	high	ADJ
gs-1727	63	11	percentage	percentage	NOUN
gs-1727	63	12	of	of	ADP
gs-1727	63	13	complete	complete	ADJ
gs-1727	63	14	responders	responder	NOUN
gs-1727	63	15	than	than	ADP
gs-1727	63	16	type	type	NOUN
gs-1727	63	17	iib	iib	NOUN
gs-1727	63	18	,	,	PUNCT
gs-1727	63	19	while	while	SCONJ
gs-1727	63	20	non	non	ADJ
gs-1727	63	21	-	-	ADJ
gs-1727	63	22	responder	responder	ADJ
gs-1727	63	23	rates	rate	NOUN
gs-1727	63	24	were	be	AUX
gs-1727	63	25	higher	high	ADJ
gs-1727	63	26	in	in	ADP
gs-1727	63	27	type	type	NOUN
gs-1727	63	28	iib	iib	NOUN
gs-1727	63	29	than	than	ADP
gs-1727	63	30	in	in	ADP
gs-1727	63	31	type	type	NOUN
gs-1727	63	32	i.	i.	NOUN
gs-1727	63	33	the	the	DET
gs-1727	63	34	median	median	PROPN
gs-1727	63	35	total	total	ADJ
gs-1727	63	36	ige	ige	PROPN
gs-1727	63	37	levels	level	NOUN
gs-1727	63	38	were	be	AUX
gs-1727	63	39	significantly	significantly	ADV
gs-1727	63	40	higher	high	ADJ
gs-1727	63	41	in	in	ADP
gs-1727	63	42	type	type	NOUN
gs-1727	63	43	i	i	PRON
gs-1727	63	44	than	than	ADP
gs-1727	63	45	in	in	ADP
gs-1727	63	46	type	type	NOUN
gs-1727	63	47	iib	iib	NOUN
gs-1727	63	48	,	,	PUNCT
gs-1727	63	49	and	and	CCONJ
gs-1727	63	50	the	the	DET
gs-1727	63	51	median	median	ADJ
gs-1727	63	52	duration	duration	NOUN
gs-1727	63	53	of	of	ADP
gs-1727	63	54	the	the	DET
gs-1727	63	55	disease	disease	NOUN
gs-1727	63	56	was	be	AUX
gs-1727	63	57	considerably	considerably	ADV
gs-1727	63	58	shorter	short	ADJ
gs-1727	63	59	in	in	ADP
gs-1727	63	60	type	type	NOUN
gs-1727	63	61	i	i	PRON
gs-1727	63	62	than	than	ADP
gs-1727	63	63	in	in	ADP
gs-1727	63	64	type	type	NOUN
gs-1727	63	65	iib	iib	NOUN
gs-1727	63	66	.	.	PUNCT
gs-1727	64	1	no	no	DET
gs-1727	64	2	significant	significant	ADJ
gs-1727	64	3	differences	difference	NOUN
gs-1727	64	4	were	be	AUX
gs-1727	64	5	observed	observe	VERB
gs-1727	64	6	between	between	ADP
gs-1727	64	7	the	the	DET
gs-1727	64	8	two	two	NUM
gs-1727	64	9	groups	group	NOUN
gs-1727	64	10	regarding	regard	VERB
gs-1727	64	11	age	age	NOUN
gs-1727	64	12	,	,	PUNCT
gs-1727	64	13	angioedema	angioedema	VERB
gs-1727	64	14	,	,	PUNCT
gs-1727	64	15	crp	crp	PROPN
gs-1727	64	16	levels	level	NOUN
gs-1727	64	17	,	,	PUNCT
gs-1727	64	18	h.	h.	PROPN
gs-1727	64	19	pylori	pylori	NOUN
gs-1727	64	20	infection	infection	NOUN
gs-1727	64	21	rates	rate	NOUN
gs-1727	64	22	,	,	PUNCT
gs-1727	64	23	anti	anti	ADJ
gs-1727	64	24	-	-	ADJ
gs-1727	64	25	tpo	tpo	ADJ
gs-1727	64	26	igg	igg	PROPN
gs-1727	64	27	levels	levels	PROPN
gs-1727	64	28	,	,	PUNCT
gs-1727	64	29	eosinopenia	eosinopenia	NOUN
gs-1727	64	30	,	,	PUNCT
gs-1727	64	31	and	and	CCONJ
gs-1727	64	32	basopenia	basopenia	NOUN
gs-1727	64	33	.	.	PUNCT
gs-1727	65	1	recent	recent	ADJ
gs-1727	65	2	reports	report	NOUN
gs-1727	65	3	characterised	characterise	VERB
gs-1727	65	4	2	2	NUM
gs-1727	65	5	possible	possible	ADJ
gs-1727	65	6	endotypes	endotype	NOUN
gs-1727	65	7	according	accord	VERB
gs-1727	65	8	to	to	ADP
gs-1727	65	9	the	the	DET
gs-1727	65	10	type	type	NOUN
gs-1727	65	11	of	of	ADP
gs-1727	65	12	mast	mast	NOUN
gs-1727	65	13	cell	cell	NOUN
gs-1727	65	14	degranulation	degranulation	NOUN
gs-1727	65	15	signals	signal	NOUN
gs-1727	65	16	:	:	PUNCT
gs-1727	65	17	type	type	NOUN
gs-1727	65	18	i	i	PRON
gs-1727	65	19	autoimmune	autoimmune	PROPN
gs-1727	65	20	csu	csu	AUX
gs-1727	65	21	mediated	mediate	VERB
gs-1727	65	22	with	with	ADP
gs-1727	65	23	ige	ige	PROPN
gs-1727	65	24	autoantibodies	autoantibody	NOUN
gs-1727	65	25	to	to	ADP
gs-1727	65	26	auto	auto	NOUN
gs-1727	65	27	-	-	PUNCT
gs-1727	65	28	allergens	allergen	NOUN
gs-1727	65	29	(	(	PUNCT
gs-1727	65	30	or	or	CCONJ
gs-1727	65	31	autoallergy	autoallergy	ADJ
gs-1727	65	32	)	)	PUNCT
gs-1727	65	33	,	,	PUNCT
gs-1727	65	34	and	and	CCONJ
gs-1727	65	35	type	type	NOUN
gs-1727	65	36	iib	iib	PROPN
gs-1727	65	37	autoimmune	autoimmune	PROPN
gs-1727	65	38	csu	csu	PROPN
gs-1727	65	39	mediated	mediate	VERB
gs-1727	65	40	with	with	ADP
gs-1727	65	41	autoantibodies	autoantibody	NOUN
gs-1727	65	42	that	that	PRON
gs-1727	65	43	target	target	VERB
gs-1727	65	44	activating	activate	VERB
gs-1727	65	45	mast	mast	NOUN
gs-1727	65	46	cells	cell	NOUN
gs-1727	65	47	receptors	receptor	NOUN
gs-1727	65	48	.	.	PUNCT
gs-1727	66	1	these	these	DET
gs-1727	66	2	2	2	NUM
gs-1727	66	3	endotypes	endotype	NOUN
gs-1727	66	4	of	of	ADP
gs-1727	66	5	autoimmune	autoimmune	ADJ
gs-1727	66	6	hypersensitivity	hypersensitivity	NOUN
gs-1727	66	7	have	have	AUX
gs-1727	66	8	been	be	AUX
gs-1727	66	9	postulated	postulate	VERB
gs-1727	66	10	as	as	ADP
gs-1727	66	11	etiologic	etiologic	ADJ
gs-1727	66	12	in	in	ADP
gs-1727	66	13	most	most	ADJ
gs-1727	66	14	csu	csu	NOUN
gs-1727	66	15	patients	patient	NOUN
gs-1727	66	16	.	.	PUNCT
gs-1727	67	1	there	there	PRON
gs-1727	67	2	is	be	VERB
gs-1727	67	3	a	a	DET
gs-1727	67	4	need	need	NOUN
gs-1727	67	5	to	to	PART
gs-1727	67	6	develop	develop	VERB
gs-1727	67	7	diagnostic	diagnostic	ADJ
gs-1727	67	8	tests	test	NOUN
gs-1727	67	9	to	to	PART
gs-1727	67	10	differentiate	differentiate	VERB
gs-1727	67	11	these	these	DET
gs-1727	67	12	two	two	NUM
gs-1727	67	13	endotypes	endotype	NOUN
gs-1727	67	14	of	of	ADP
gs-1727	67	15	csu	csu	NOUN
gs-1727	67	16	to	to	PART
gs-1727	67	17	tailor	tailor	VERB
gs-1727	67	18	the	the	DET
gs-1727	67	19	appropriate	appropriate	ADJ
gs-1727	67	20	treatment	treatment	NOUN
gs-1727	67	21	and	and	CCONJ
gs-1727	67	22	help	help	VERB
gs-1727	67	23	each	each	DET
gs-1727	67	24	patient	patient	NOUN
gs-1727	67	25	achieve	achieve	VERB
gs-1727	67	26	remission	remission	NOUN
gs-1727	67	27	8	8	NUM
gs-1727	67	28	.	.	PUNCT
gs-1727	68	1	the	the	DET
gs-1727	68	2	study	study	NOUN
gs-1727	68	3	's	's	PART
gs-1727	68	4	findings	finding	NOUN
gs-1727	68	5	suggest	suggest	VERB
gs-1727	68	6	that	that	SCONJ
gs-1727	68	7	total	total	ADJ
gs-1727	68	8	ige	ige	PROPN
gs-1727	68	9	levels	level	NOUN
gs-1727	68	10	and	and	CCONJ
gs-1727	68	11	ana	ana	PROPN
gs-1727	68	12	can	can	AUX
gs-1727	68	13	help	help	VERB
gs-1727	68	14	identify	identify	VERB
gs-1727	68	15	patients	patient	NOUN
gs-1727	68	16	with	with	ADP
gs-1727	68	17	type	type	NOUN
gs-1727	68	18	i	i	PRON
gs-1727	68	19	and	and	CCONJ
gs-1727	68	20	type	type	NOUN
gs-1727	68	21	iib	iib	NOUN
gs-1727	68	22	autoimmunity	autoimmunity	NOUN
gs-1727	68	23	and	and	CCONJ
gs-1727	68	24	predict	predict	VERB
gs-1727	68	25	their	their	PRON
gs-1727	68	26	response	response	NOUN
gs-1727	68	27	to	to	AUX
gs-1727	68	28	omalizumab	omalizumab	NOUN
gs-1727	68	29	9,10	9,10	NUM
gs-1727	68	30	.	.	PUNCT
gs-1727	69	1	many	many	ADJ
gs-1727	69	2	studies	study	NOUN
gs-1727	69	3	indicate	indicate	VERB
gs-1727	69	4	that	that	SCONJ
gs-1727	69	5	total	total	ADJ
gs-1727	69	6	ige	ige	PROPN
gs-1727	69	7	levels	level	NOUN
gs-1727	69	8	affect	affect	VERB
gs-1727	69	9	the	the	DET
gs-1727	69	10	response	response	NOUN
gs-1727	69	11	to	to	ADP
gs-1727	69	12	omalizumab	omalizumab	NOUN
gs-1727	69	13	.	.	PUNCT
gs-1727	70	1	baseline	baseline	PROPN
gs-1727	70	2	total	total	ADJ
gs-1727	70	3	ige	ige	PROPN
gs-1727	70	4	levels	level	NOUN
gs-1727	70	5	above	above	ADP
gs-1727	70	6	43	43	NUM
gs-1727	70	7	iu	iu	NOUN
gs-1727	70	8	/	/	SYM
gs-1727	70	9	l	l	NOUN
gs-1727	70	10	and	and	CCONJ
gs-1727	70	11	twofold	twofold	NOUN
gs-1727	70	12	or	or	CCONJ
gs-1727	70	13	more	more	ADV
gs-1727	70	14	increased	increase	VERB
gs-1727	70	15	ige	ige	PROPN
gs-1727	70	16	levels	level	NOUN
gs-1727	70	17	at	at	ADP
gs-1727	70	18	week	week	NOUN
gs-1727	70	19	4	4	NUM
gs-1727	70	20	were	be	AUX
gs-1727	70	21	correlated	correlate	VERB
gs-1727	70	22	with	with	ADP
gs-1727	70	23	the	the	DET
gs-1727	70	24	improvement	improvement	NOUN
gs-1727	70	25	of	of	ADP
gs-1727	70	26	csu	csu	PROPN
gs-1727	70	27	at	at	ADP
gs-1727	70	28	week	week	NOUN
gs-1727	70	29	12	12	NUM
gs-1727	70	30	of	of	ADP
gs-1727	70	31	treatment	treatment	NOUN
gs-1727	70	32	as	as	SCONJ
gs-1727	70	33	assessed	assess	VERB
gs-1727	70	34	by	by	ADP
gs-1727	70	35	uas11	uas11	PROPN
gs-1727	70	36	.	.	PUNCT
gs-1727	71	1	weller	weller	PROPN
gs-1727	71	2	et	et	PROPN
gs-1727	71	3	al	al	PROPN
gs-1727	71	4	.	.	PROPN
gs-1727	71	5	found	find	VERB
gs-1727	71	6	that	that	SCONJ
gs-1727	71	7	elevated	elevated	ADJ
gs-1727	71	8	total	total	ADJ
gs-1727	71	9	ige	ige	PROPN
gs-1727	71	10	levels	level	NOUN
gs-1727	71	11	were	be	AUX
gs-1727	71	12	common	common	ADJ
gs-1727	71	13	in	in	ADP
gs-1727	71	14	complete	complete	ADJ
gs-1727	71	15	responders	responder	NOUN
gs-1727	71	16	(	(	PUNCT
gs-1727	71	17	77.5	77.5	NUM
gs-1727	71	18	%	%	NOUN
gs-1727	71	19	)	)	PUNCT
gs-1727	71	20	,	,	PUNCT
gs-1727	71	21	and	and	CCONJ
gs-1727	71	22	rarely	rarely	ADV
gs-1727	71	23	detected	detect	VERB
gs-1727	71	24	in	in	ADP
gs-1727	71	25	non	non	NOUN
gs-1727	71	26	-	-	NOUN
gs-1727	71	27	responders	responder	NOUN
gs-1727	71	28	(	(	PUNCT
gs-1727	71	29	20	20	NUM
gs-1727	71	30	%	%	NOUN
gs-1727	71	31	)	)	PUNCT
gs-1727	71	32	to	to	PART
gs-1727	71	33	omalizumab12	omalizumab12	VERB
gs-1727	71	34	.	.	PUNCT
gs-1727	72	1	asero	asero	PROPN
gs-1727	72	2	has	have	AUX
gs-1727	72	3	recently	recently	ADV
gs-1727	72	4	confirmed	confirm	VERB
gs-1727	72	5	that	that	SCONJ
gs-1727	72	6	most	most	ADJ
gs-1727	72	7	early	early	ADJ
gs-1727	72	8	responders	responder	NOUN
gs-1727	72	9	to	to	PART
gs-1727	72	10	omalizumab	omalizumab	NOUN
gs-1727	72	11	have	have	AUX
gs-1727	72	12	elevated	elevate	VERB
gs-1727	72	13	baseline	baseline	ADJ
gs-1727	72	14	total	total	NOUN
gs-1727	72	15	ige	ige	PROPN
gs-1727	72	16	13	13	NUM
gs-1727	72	17	.	.	PUNCT
gs-1727	73	1	the	the	DET
gs-1727	73	2	response	response	NOUN
gs-1727	73	3	to	to	ADP
gs-1727	73	4	omalizumab	omalizumab	NOUN
gs-1727	73	5	in	in	ADP
gs-1727	73	6	severe	severe	ADJ
gs-1727	73	7	chronic	chronic	ADJ
gs-1727	73	8	spontaneous	spontaneous	ADJ
gs-1727	73	9	urticaria	urticaria	NOUN
gs-1727	73	10	(	(	PUNCT
gs-1727	73	11	csu	csu	PROPN
gs-1727	73	12	)	)	PUNCT
gs-1727	73	13	largely	largely	ADV
gs-1727	73	14	depends	depend	VERB
gs-1727	73	15	on	on	ADP
gs-1727	73	16	the	the	DET
gs-1727	73	17	autoimmune	autoimmune	ADJ
gs-1727	73	18	or	or	CCONJ
gs-1727	73	19	autoallergic	autoallergic	NOUN
gs-1727	73	20	endotype	endotype	NOUN
gs-1727	73	21	of	of	ADP
gs-1727	73	22	the	the	DET
gs-1727	73	23	disease	disease	NOUN
gs-1727	73	24	,	,	PUNCT
gs-1727	73	25	and	and	CCONJ
gs-1727	73	26	total	total	ADJ
gs-1727	73	27	ige	ige	PROPN
gs-1727	73	28	levels	level	NOUN
gs-1727	73	29	are	be	AUX
gs-1727	73	30	the	the	DET
gs-1727	73	31	most	most	ADV
gs-1727	73	32	reliable	reliable	ADJ
gs-1727	73	33	prognostic	prognostic	ADJ
gs-1727	73	34	marker	marker	NOUN
gs-1727	73	35	for	for	ADP
gs-1727	73	36	omalizumab	omalizumab	NOUN
gs-1727	73	37	response	response	NOUN
gs-1727	73	38	.	.	PUNCT
gs-1727	74	1	the	the	DET
gs-1727	74	2	study	study	NOUN
gs-1727	74	3	concludes	conclude	VERB
gs-1727	74	4	that	that	SCONJ
gs-1727	74	5	thyroid	thyroid	NOUN
gs-1727	74	6	autoimmunity	autoimmunity	NOUN
gs-1727	74	7	alone	alone	ADV
gs-1727	74	8	can	can	AUX
gs-1727	74	9	not	not	PART
gs-1727	74	10	be	be	AUX
gs-1727	74	11	used	use	VERB
gs-1727	74	12	as	as	ADP
gs-1727	74	13	a	a	DET
gs-1727	74	14	clinical	clinical	ADJ
gs-1727	74	15	predictor	predictor	NOUN
gs-1727	74	16	of	of	ADP
gs-1727	74	17	omalizumab	omalizumab	NOUN
gs-1727	74	18	response	response	NOUN
gs-1727	74	19	in	in	ADP
gs-1727	74	20	patients	patient	NOUN
gs-1727	74	21	with	with	ADP
gs-1727	74	22	severe	severe	ADJ
gs-1727	74	23	csu	csu	PROPN
gs-1727	74	24	.	.	PUNCT
gs-1727	75	1	total	total	ADJ
gs-1727	75	2	ige	ige	PROPN
gs-1727	75	3	levels	level	NOUN
gs-1727	75	4	remain	remain	VERB
gs-1727	75	5	the	the	DET
gs-1727	75	6	only	only	ADJ
gs-1727	75	7	and	and	CCONJ
gs-1727	75	8	most	most	ADV
gs-1727	75	9	reliable	reliable	ADJ
gs-1727	75	10	prognostic	prognostic	ADJ
gs-1727	75	11	marker	marker	NOUN
gs-1727	75	12	for	for	ADP
gs-1727	75	13	omalizumab	omalizumab	NOUN
gs-1727	75	14	response	response	NOUN
gs-1727	75	15	in	in	ADP
gs-1727	75	16	these	these	DET
gs-1727	75	17	patients14	patients14	NOUN
gs-1727	75	18	.	.	PUNCT
gs-1727	76	1	according	accord	VERB
gs-1727	76	2	to	to	ADP
gs-1727	76	3	our	our	PRON
gs-1727	76	4	results	result	NOUN
gs-1727	76	5	,	,	PUNCT
gs-1727	76	6	too	too	ADV
gs-1727	76	7	,	,	PUNCT
gs-1727	76	8	there	there	PRON
gs-1727	76	9	was	be	VERB
gs-1727	76	10	no	no	DET
gs-1727	76	11	difference	difference	NOUN
gs-1727	76	12	in	in	ADP
gs-1727	76	13	thyroid	thyroid	NOUN
gs-1727	76	14	autoimmunity	autoimmunity	NOUN
gs-1727	76	15	.	.	PUNCT
gs-1727	77	1	the	the	DET
gs-1727	77	2	study	study	NOUN
gs-1727	77	3	's	's	PART
gs-1727	77	4	limitations	limitation	NOUN
gs-1727	77	5	include	include	VERB
gs-1727	77	6	small	small	ADJ
gs-1727	77	7	sample	sample	NOUN
gs-1727	77	8	size	size	NOUN
gs-1727	77	9	,	,	PUNCT
gs-1727	77	10	retrospective	retrospective	ADJ
gs-1727	77	11	design	design	NOUN
gs-1727	77	12	,	,	PUNCT
gs-1727	77	13	and	and	CCONJ
gs-1727	77	14	lack	lack	NOUN
gs-1727	77	15	of	of	ADP
gs-1727	77	16	a	a	DET
gs-1727	77	17	control	control	NOUN
gs-1727	77	18	group	group	NOUN
gs-1727	77	19	.	.	PUNCT
gs-1727	78	1	further	further	ADJ
gs-1727	78	2	studies	study	NOUN
gs-1727	78	3	with	with	ADP
gs-1727	78	4	a	a	DET
gs-1727	78	5	larger	large	ADJ
gs-1727	78	6	sample	sample	NOUN
gs-1727	78	7	size	size	NOUN
gs-1727	78	8	,	,	PUNCT
gs-1727	78	9	prospective	prospective	ADJ
gs-1727	78	10	design	design	NOUN
gs-1727	78	11	,	,	PUNCT
gs-1727	78	12	and	and	CCONJ
gs-1727	78	13	a	a	DET
gs-1727	78	14	control	control	NOUN
gs-1727	78	15	group	group	NOUN
gs-1727	78	16	are	be	AUX
gs-1727	78	17	needed	need	VERB
gs-1727	78	18	to	to	PART
gs-1727	78	19	validate	validate	VERB
gs-1727	78	20	the	the	DET
gs-1727	78	21	findings	finding	NOUN
gs-1727	78	22	.	.	PUNCT
gs-1727	79	1	nevertheless	nevertheless	ADV
gs-1727	79	2	,	,	PUNCT
gs-1727	79	3	the	the	DET
gs-1727	79	4	study	study	NOUN
gs-1727	79	5	provides	provide	VERB
gs-1727	79	6	important	important	ADJ
gs-1727	79	7	insights	insight	NOUN
gs-1727	79	8	into	into	ADP
gs-1727	79	9	the	the	DET
gs-1727	79	10	use	use	NOUN
gs-1727	79	11	of	of	ADP
gs-1727	79	12	omalizumab	omalizumab	NOUN
gs-1727	79	13	in	in	ADP
gs-1727	79	14	patients	patient	NOUN
gs-1727	79	15	with	with	ADP
gs-1727	79	16	csu	csu	PROPN
gs-1727	79	17	and	and	CCONJ
gs-1727	79	18	different	different	ADJ
gs-1727	79	19	types	type	NOUN
gs-1727	79	20	of	of	ADP
gs-1727	79	21	autoimmunity	autoimmunity	NOUN
gs-1727	79	22	.	.	PUNCT
gs-1727	80	1	overall	overall	ADV
gs-1727	80	2	,	,	PUNCT
gs-1727	80	3	the	the	DET
gs-1727	80	4	study	study	NOUN
gs-1727	80	5	highlights	highlight	VERB
gs-1727	80	6	the	the	DET
gs-1727	80	7	importance	importance	NOUN
gs-1727	80	8	of	of	ADP
gs-1727	80	9	personalised	personalised	ADJ
gs-1727	80	10	medicine	medicine	NOUN
gs-1727	80	11	in	in	ADP
gs-1727	80	12	managing	manage	VERB
gs-1727	80	13	csu	csu	PROPN
gs-1727	80	14	patients	patient	NOUN
gs-1727	80	15	,	,	PUNCT
gs-1727	80	16	considering	consider	VERB
gs-1727	80	17	their	their	PRON
gs-1727	80	18	autoimmunity	autoimmunity	NOUN
gs-1727	80	19	status	status	NOUN
gs-1727	80	20	and	and	CCONJ
gs-1727	80	21	laboratory	laboratory	NOUN
gs-1727	80	22	data	datum	NOUN
gs-1727	80	23	.	.	PUNCT
gs-1727	81	1	georgian	georgian	ADJ
gs-1727	81	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-1727	81	3	მეცნიერები	მეცნიერები	NOUN
gs-1727	81	4	ტ.	ტ.	VERB
gs-1727	81	5	5	5	NUM
gs-1727	81	6	n	n	PRON
gs-1727	81	7	2	2	NUM
gs-1727	81	8	,	,	PUNCT
gs-1727	81	9	2023	2023	NUM
gs-1727	81	10	114	114	NUM
gs-1727	81	11	conclusion	conclusion	NOUN
gs-1727	81	12	this	this	DET
gs-1727	81	13	study	study	NOUN
gs-1727	81	14	evaluated	evaluate	VERB
gs-1727	81	15	the	the	DET
gs-1727	81	16	clinical	clinical	ADJ
gs-1727	81	17	response	response	NOUN
gs-1727	81	18	to	to	ADP
gs-1727	81	19	omalizumab	omalizumab	NOUN
gs-1727	81	20	in	in	ADP
gs-1727	81	21	patients	patient	NOUN
gs-1727	81	22	with	with	ADP
gs-1727	81	23	chronic	chronic	ADJ
gs-1727	81	24	spontaneous	spontaneous	ADJ
gs-1727	81	25	urticaria	urticaria	NOUN
gs-1727	81	26	(	(	PUNCT
gs-1727	81	27	csu	csu	PROPN
gs-1727	81	28	)	)	PUNCT
gs-1727	81	29	and	and	CCONJ
gs-1727	81	30	type	type	NOUN
gs-1727	81	31	i	i	PRON
gs-1727	81	32	and	and	CCONJ
gs-1727	81	33	type	type	NOUN
gs-1727	81	34	iib	iib	NOUN
gs-1727	81	35	autoimmunity	autoimmunity	NOUN
gs-1727	81	36	.	.	PUNCT
gs-1727	82	1	the	the	DET
gs-1727	82	2	results	result	NOUN
gs-1727	82	3	showed	show	VERB
gs-1727	82	4	that	that	DET
gs-1727	82	5	type	type	NOUN
gs-1727	82	6	i	i	PRON
gs-1727	82	7	autoimmunity	autoimmunity	NOUN
gs-1727	82	8	had	have	VERB
gs-1727	82	9	a	a	DET
gs-1727	82	10	higher	high	ADJ
gs-1727	82	11	percentage	percentage	NOUN
gs-1727	82	12	of	of	ADP
gs-1727	82	13	complete	complete	ADJ
gs-1727	82	14	responders	responder	NOUN
gs-1727	82	15	than	than	ADP
gs-1727	82	16	type	type	NOUN
gs-1727	82	17	iib	iib	NOUN
gs-1727	82	18	,	,	PUNCT
gs-1727	82	19	while	while	SCONJ
gs-1727	82	20	non	non	ADJ
gs-1727	82	21	-	-	ADJ
gs-1727	82	22	responder	responder	ADJ
gs-1727	82	23	rates	rate	NOUN
gs-1727	82	24	were	be	AUX
gs-1727	82	25	higher	high	ADJ
gs-1727	82	26	in	in	ADP
gs-1727	82	27	type	type	NOUN
gs-1727	82	28	iib	iib	NOUN
gs-1727	82	29	than	than	ADP
gs-1727	82	30	in	in	ADP
gs-1727	82	31	type	type	NOUN
gs-1727	82	32	i.	i.	NOUN
gs-1727	82	33	the	the	DET
gs-1727	82	34	median	median	PROPN
gs-1727	82	35	duration	duration	NOUN
gs-1727	82	36	of	of	ADP
gs-1727	82	37	the	the	DET
gs-1727	82	38	disease	disease	NOUN
gs-1727	82	39	was	be	AUX
gs-1727	82	40	significantly	significantly	ADV
gs-1727	82	41	shorter	short	ADJ
gs-1727	82	42	in	in	ADP
gs-1727	82	43	type	type	NOUN
gs-1727	82	44	i	i	PRON
gs-1727	82	45	than	than	ADP
gs-1727	82	46	in	in	ADP
gs-1727	82	47	type	type	NOUN
gs-1727	82	48	iib	iib	NOUN
gs-1727	82	49	.	.	PUNCT
gs-1727	83	1	these	these	DET
gs-1727	83	2	findings	finding	NOUN
gs-1727	83	3	suggest	suggest	VERB
gs-1727	83	4	that	that	SCONJ
gs-1727	83	5	omalizumab	omalizumab	NOUN
gs-1727	83	6	may	may	AUX
gs-1727	83	7	be	be	AUX
gs-1727	83	8	more	more	ADV
gs-1727	83	9	effective	effective	ADJ
gs-1727	83	10	in	in	ADP
gs-1727	83	11	type	type	NOUN
gs-1727	83	12	i	i	PRON
gs-1727	83	13	autoimmunity	autoimmunity	NOUN
gs-1727	83	14	than	than	ADP
gs-1727	83	15	type	type	NOUN
gs-1727	83	16	iib	iib	NOUN
gs-1727	83	17	autoimmunity	autoimmunity	NOUN
gs-1727	83	18	in	in	ADP
gs-1727	83	19	csu	csu	PROPN
gs-1727	83	20	patients	patient	NOUN
gs-1727	83	21	.	.	PUNCT
gs-1727	84	1	the	the	DET
gs-1727	84	2	results	result	NOUN
gs-1727	84	3	of	of	ADP
gs-1727	84	4	our	our	PRON
gs-1727	84	5	study	study	NOUN
gs-1727	84	6	indicate	indicate	VERB
gs-1727	84	7	that	that	SCONJ
gs-1727	84	8	total	total	ADJ
gs-1727	84	9	ige	ige	PROPN
gs-1727	84	10	and	and	CCONJ
gs-1727	84	11	ana	ana	PROPN
gs-1727	84	12	,	,	PUNCT
gs-1727	84	13	two	two	NUM
gs-1727	84	14	simple	simple	ADJ
gs-1727	84	15	and	and	CCONJ
gs-1727	84	16	inexpensive	inexpensive	ADJ
gs-1727	84	17	tests	test	NOUN
gs-1727	84	18	,	,	PUNCT
gs-1727	84	19	can	can	AUX
gs-1727	84	20	be	be	AUX
gs-1727	84	21	used	use	VERB
gs-1727	84	22	to	to	PART
gs-1727	84	23	predict	predict	VERB
gs-1727	84	24	the	the	DET
gs-1727	84	25	efficacy	efficacy	NOUN
gs-1727	84	26	of	of	ADP
gs-1727	84	27	omalizumab	omalizumab	NOUN
gs-1727	84	28	.	.	PUNCT
gs-1727	85	1	further	further	ADJ
gs-1727	85	2	studies	study	NOUN
gs-1727	85	3	are	be	AUX
gs-1727	85	4	needed	need	VERB
gs-1727	85	5	to	to	PART
gs-1727	85	6	evaluate	evaluate	VERB
gs-1727	85	7	the	the	DET
gs-1727	85	8	mechanism	mechanism	NOUN
gs-1727	85	9	underlying	underlie	VERB
gs-1727	85	10	the	the	DET
gs-1727	85	11	difference	difference	NOUN
gs-1727	85	12	in	in	ADP
gs-1727	85	13	response	response	NOUN
gs-1727	85	14	to	to	ADP
gs-1727	85	15	omalizumab	omalizumab	NOUN
gs-1727	85	16	and	and	CCONJ
gs-1727	85	17	the	the	DET
gs-1727	85	18	use	use	NOUN
gs-1727	85	19	of	of	ADP
gs-1727	85	20	different	different	ADJ
gs-1727	85	21	treatment	treatment	NOUN
gs-1727	85	22	options	option	NOUN
gs-1727	85	23	for	for	ADP
gs-1727	85	24	patients	patient	NOUN
gs-1727	85	25	with	with	ADP
gs-1727	85	26	different	different	ADJ
gs-1727	85	27	types	type	NOUN
gs-1727	85	28	of	of	ADP
gs-1727	85	29	autoimmunity	autoimmunity	NOUN
gs-1727	85	30	.	.	PUNCT
gs-1727	86	1	declaration	declaration	NOUN
gs-1727	86	2	of	of	ADP
gs-1727	86	3	conflicting	conflicting	ADJ
gs-1727	86	4	interests	interest	NOUN
gs-1727	86	5	the	the	DET
gs-1727	86	6	author(s	author(s	NOUN
gs-1727	86	7	)	)	PUNCT
gs-1727	86	8	declared	declare	VERB
gs-1727	86	9	no	no	DET
gs-1727	86	10	potential	potential	ADJ
gs-1727	86	11	conflicts	conflict	NOUN
gs-1727	86	12	of	of	ADP
gs-1727	86	13	interest	interest	NOUN
gs-1727	86	14	with	with	ADP
gs-1727	86	15	respect	respect	NOUN
gs-1727	86	16	to	to	ADP
gs-1727	86	17	the	the	DET
gs-1727	86	18	research	research	NOUN
gs-1727	86	19	,	,	PUNCT
gs-1727	86	20	authorship	authorship	NOUN
gs-1727	86	21	,	,	PUNCT
gs-1727	86	22	and/or	and/or	CCONJ
gs-1727	86	23	publication	publication	NOUN
gs-1727	86	24	of	of	ADP
gs-1727	86	25	this	this	DET
gs-1727	86	26	article	article	NOUN
gs-1727	86	27	.	.	PUNCT
gs-1727	87	1	funding	fund	VERB
gs-1727	87	2	the	the	DET
gs-1727	87	3	author(s	author(s	NOUN
gs-1727	87	4	)	)	PUNCT
gs-1727	87	5	received	receive	VERB
gs-1727	87	6	financial	financial	ADJ
gs-1727	87	7	support	support	NOUN
gs-1727	87	8	for	for	ADP
gs-1727	87	9	this	this	DET
gs-1727	87	10	article	article	NOUN
gs-1727	87	11	's	's	PART
gs-1727	87	12	research	research	NOUN
gs-1727	87	13	,	,	PUNCT
gs-1727	87	14	authorship	authorship	NOUN
gs-1727	87	15	and/or	and/or	CCONJ
gs-1727	87	16	publication	publication	NOUN
gs-1727	87	17	(	(	PUNCT
gs-1727	87	18	shota	shota	PROPN
gs-1727	87	19	rustaveli	rustaveli	ADJ
gs-1727	87	20	national	national	PROPN
gs-1727	87	21	science	science	PROPN
gs-1727	87	22	foundation	foundation	PROPN
gs-1727	87	23	of	of	ADP
gs-1727	87	24	georgia	georgia	PROPN
gs-1727	87	25	,	,	PUNCT
gs-1727	87	26	grant	grant	VERB
gs-1727	87	27	number	number	NOUN
gs-1727	87	28	№	№	VERB
gs-1727	87	29	phdf-21	phdf-21	NOUN
gs-1727	87	30	-	-	PUNCT
gs-1727	87	31	3221	3221	NUM
gs-1727	87	32	)	)	PUNCT
gs-1727	87	33	.	.	PUNCT
gs-1727	88	1	references	reference	NOUN
gs-1727	88	2	1	1	NUM
gs-1727	88	3	.	.	PUNCT
gs-1727	88	4	zuberbier	zuberbier	PROPN
gs-1727	88	5	t	t	PROPN
gs-1727	88	6	,	,	PUNCT
gs-1727	88	7	abdul	abdul	PROPN
gs-1727	88	8	latiff	latiff	PROPN
gs-1727	88	9	ah	ah	INTJ
gs-1727	88	10	,	,	PUNCT
gs-1727	88	11	abuzakouk	abuzakouk	PROPN
gs-1727	88	12	m	m	PROPN
gs-1727	88	13	,	,	PUNCT
gs-1727	88	14	aquilina	aquilina	PROPN
gs-1727	88	15	s	s	PROPN
gs-1727	88	16	,	,	PUNCT
gs-1727	88	17	asero	asero	NOUN
gs-1727	88	18	r	r	NOUN
gs-1727	88	19	,	,	PUNCT
gs-1727	88	20	baker	baker	PROPN
gs-1727	88	21	d	d	PROPN
gs-1727	88	22	,	,	PUNCT
gs-1727	88	23	et	et	PROPN
gs-1727	88	24	al	al	PROPN
gs-1727	88	25	.	.	PUNCT
gs-1727	89	1	the	the	DET
gs-1727	89	2	international	international	PROPN
gs-1727	89	3	eaaci	eaaci	PROPN
gs-1727	89	4	/	/	SYM
gs-1727	89	5	ga2	ga2	PROPN
gs-1727	89	6	len	len	PROPN
gs-1727	89	7	/	/	SYM
gs-1727	89	8	euroguiderm	euroguiderm	NOUN
gs-1727	89	9	/	/	SYM
gs-1727	89	10	apaaaci	apaaaci	NOUN
gs-1727	89	11	guideline	guideline	NOUN
gs-1727	89	12	for	for	ADP
gs-1727	89	13	the	the	DET
gs-1727	89	14	definition	definition	NOUN
gs-1727	89	15	,	,	PUNCT
gs-1727	89	16	classification	classification	NOUN
gs-1727	89	17	,	,	PUNCT
gs-1727	89	18	diagnosis	diagnosis	NOUN
gs-1727	89	19	,	,	PUNCT
gs-1727	89	20	and	and	CCONJ
gs-1727	89	21	management	management	NOUN
gs-1727	89	22	of	of	ADP
gs-1727	89	23	urticaria	urticaria	NOUN
gs-1727	89	24	.	.	PUNCT
gs-1727	90	1	allergy	allergy	NOUN
gs-1727	90	2	2022	2022	NUM
gs-1727	90	3	;	;	PUNCT
gs-1727	90	4	77:734	77:734	NUM
gs-1727	90	5	-	-	SYM
gs-1727	90	6	66	66	NUM
gs-1727	90	7	.	.	PUNCT
gs-1727	91	1	2	2	NUM
gs-1727	91	2	.	.	X
gs-1727	91	3	gericke	gericke	PROPN
gs-1727	91	4	j	j	PROPN
gs-1727	91	5	,	,	PUNCT
gs-1727	91	6	metz	metz	PROPN
gs-1727	91	7	m	m	PROPN
gs-1727	91	8	,	,	PUNCT
gs-1727	91	9	ohanyan	ohanyan	PROPN
gs-1727	91	10	t	t	PROPN
gs-1727	91	11	,	,	PUNCT
gs-1727	91	12	et	et	PROPN
gs-1727	91	13	al	al	PROPN
gs-1727	91	14	.	.	PROPN
gs-1727	92	1	serum	serum	PROPN
gs-1727	92	2	autoreactivity	autoreactivity	PROPN
gs-1727	92	3	predicts	predict	VERB
gs-1727	92	4	time	time	NOUN
gs-1727	92	5	to	to	PART
gs-1727	92	6	response	response	VERB
gs-1727	92	7	to	to	ADP
gs-1727	92	8	omalizumab	omalizumab	NOUN
gs-1727	92	9	therapy	therapy	NOUN
gs-1727	92	10	in	in	ADP
gs-1727	92	11	chronic	chronic	ADJ
gs-1727	92	12	spontaneous	spontaneous	ADJ
gs-1727	92	13	urticaria	urticaria	NOUN
gs-1727	92	14	.	.	PUNCT
gs-1727	93	1	j	j	PROPN
gs-1727	93	2	allergy	allergy	PROPN
gs-1727	93	3	clin	clin	PROPN
gs-1727	93	4	immunol	immunol	PROPN
gs-1727	93	5	2017;139:105961	2017;139:105961	PROPN
gs-1727	93	6	.	.	PUNCT
gs-1727	94	1	3	3	X
gs-1727	94	2	.	.	X
gs-1727	94	3	straesser	straesser	PROPN
gs-1727	94	4	md	md	PROPN
gs-1727	94	5	,	,	PUNCT
gs-1727	94	6	oliver	oliver	PROPN
gs-1727	94	7	e	e	PROPN
gs-1727	94	8	,	,	PUNCT
gs-1727	94	9	palacios	palacios	PROPN
gs-1727	94	10	t	t	PROPN
gs-1727	94	11	,	,	PUNCT
gs-1727	94	12	et	et	PROPN
gs-1727	94	13	al	al	PROPN
gs-1727	94	14	.	.	PROPN
gs-1727	94	15	serum	serum	PROPN
gs-1727	94	16	ige	ige	PROPN
gs-1727	94	17	as	as	ADP
gs-1727	94	18	an	an	DET
gs-1727	94	19	immunological	immunological	ADJ
gs-1727	94	20	marker	marker	NOUN
gs-1727	94	21	to	to	PART
gs-1727	94	22	predict	predict	VERB
gs-1727	94	23	response	response	NOUN
gs-1727	94	24	to	to	AUX
gs-1727	94	25	omalizumab	omalizumab	NOUN
gs-1727	94	26	treatment	treatment	NOUN
gs-1727	94	27	in	in	ADP
gs-1727	94	28	symptomatic	symptomatic	ADJ
gs-1727	94	29	chronic	chronic	ADJ
gs-1727	94	30	urticaria	urticaria	NOUN
gs-1727	94	31	.	.	PUNCT
gs-1727	95	1	j	j	PROPN
gs-1727	95	2	allergy	allergy	PROPN
gs-1727	95	3	clin	clin	PROPN
gs-1727	95	4	immunol	immunol	PROPN
gs-1727	95	5	pract	pract	PROPN
gs-1727	95	6	2018;6:1386	2018;6:1386	PROPN
gs-1727	95	7	-	-	SYM
gs-1727	95	8	88	88	NUM
gs-1727	95	9	.	.	PUNCT
gs-1727	95	10	4	4	NUM
gs-1727	95	11	.	.	X
gs-1727	95	12	ertas	ertas	PROPN
gs-1727	95	13	r	r	PROPN
gs-1727	95	14	,	,	PUNCT
gs-1727	95	15	ozyurt	ozyurt	NOUN
gs-1727	95	16	k	k	NOUN
gs-1727	95	17	,	,	PUNCT
gs-1727	95	18	atasoy	atasoy	PROPN
gs-1727	95	19	m	m	PROPN
gs-1727	95	20	,	,	PUNCT
gs-1727	95	21	hawro	hawro	PROPN
gs-1727	95	22	t	t	PROPN
gs-1727	95	23	,	,	PUNCT
gs-1727	95	24	maurer	maurer	PROPN
gs-1727	95	25	m.	m.	VERB
gs-1727	95	26	the	the	DET
gs-1727	95	27	clinical	clinical	ADJ
gs-1727	95	28	response	response	NOUN
gs-1727	95	29	to	to	ADP
gs-1727	95	30	omalizumab	omalizumab	NOUN
gs-1727	95	31	in	in	ADP
gs-1727	95	32	chronic	chronic	ADJ
gs-1727	95	33	spontaneous	spontaneous	ADJ
gs-1727	95	34	urticaria	urticaria	NOUN
gs-1727	95	35	patients	patient	NOUN
gs-1727	95	36	is	be	AUX
gs-1727	95	37	linked	link	VERB
gs-1727	95	38	and	and	CCONJ
gs-1727	95	39	predicted	predict	VERB
gs-1727	95	40	by	by	ADP
gs-1727	95	41	ige	ige	PROPN
gs-1727	95	42	levels	level	NOUN
gs-1727	95	43	and	and	CCONJ
gs-1727	95	44	their	their	PRON
gs-1727	95	45	change	change	NOUN
gs-1727	95	46	.	.	PUNCT
gs-1727	96	1	allergy	allergy	NOUN
gs-1727	96	2	2018;73:705	2018;73:705	NUM
gs-1727	96	3	-	-	SYM
gs-1727	96	4	12	12	NUM
gs-1727	96	5	.	.	PUNCT
gs-1727	96	6	5	5	X
gs-1727	96	7	.	.	X
gs-1727	97	1	schmetzer	schmetzer	PROPN
gs-1727	97	2	o	o	PROPN
gs-1727	97	3	,	,	PUNCT
gs-1727	97	4	lakin	lakin	PROPN
gs-1727	97	5	e	e	PROPN
gs-1727	97	6	,	,	PUNCT
gs-1727	97	7	topal	topal	PROPN
gs-1727	97	8	fa	fa	PROPN
gs-1727	97	9	,	,	PUNCT
gs-1727	97	10	et	et	PROPN
gs-1727	97	11	al	al	PROPN
gs-1727	97	12	.	.	PUNCT
gs-1727	97	13	il-24	il-24	PUNCT
gs-1727	97	14	is	be	AUX
gs-1727	97	15	a	a	DET
gs-1727	97	16	common	common	ADJ
gs-1727	97	17	and	and	CCONJ
gs-1727	97	18	specific	specific	ADJ
gs-1727	97	19	autoantigen	autoantigen	NOUN
gs-1727	97	20	of	of	ADP
gs-1727	97	21	ige	ige	PROPN
gs-1727	97	22	in	in	ADP
gs-1727	97	23	patients	patient	NOUN
gs-1727	97	24	with	with	ADP
gs-1727	97	25	chronic	chronic	ADJ
gs-1727	97	26	spontaneous	spontaneous	ADJ
gs-1727	97	27	urticaria	urticaria	NOUN
gs-1727	97	28	.	.	PUNCT
gs-1727	98	1	j	j	PROPN
gs-1727	98	2	allergy	allergy	PROPN
gs-1727	98	3	clin	clin	PROPN
gs-1727	98	4	immunol	immunol	PROPN
gs-1727	98	5	2018;142:876	2018;142:876	PROPN
gs-1727	98	6	-	-	SYM
gs-1727	98	7	82	82	NUM
gs-1727	98	8	.	.	NOUN
gs-1727	98	9	6	6	NUM
gs-1727	98	10	.	.	X
gs-1727	99	1	kolkhir	kolkhir	PROPN
gs-1727	99	2	p	p	NOUN
gs-1727	99	3	,	,	PUNCT
gs-1727	99	4	altrichter	altrichter	PROPN
gs-1727	99	5	s	s	PART
gs-1727	99	6	,	,	PUNCT
gs-1727	99	7	asero	asero	NOUN
gs-1727	99	8	r	r	NOUN
gs-1727	99	9	,	,	PUNCT
gs-1727	99	10	daschner	daschner	NOUN
gs-1727	99	11	a	a	X
gs-1727	99	12	,	,	PUNCT
gs-1727	99	13	ferrer	ferrer	PROPN
gs-1727	99	14	m	m	PROPN
gs-1727	99	15	,	,	PUNCT
gs-1727	99	16	giménez	giménez	PROPN
gs-1727	99	17	-	-	PUNCT
gs-1727	99	18	arnau	arnau	PROPN
gs-1727	99	19	a	a	DET
gs-1727	99	20	,	,	PUNCT
gs-1727	99	21	hawro	hawro	PROPN
gs-1727	99	22	t	t	PROPN
gs-1727	99	23	,	,	PUNCT
gs-1727	99	24	jakob	jakob	PROPN
gs-1727	99	25	t	t	PROPN
gs-1727	99	26	,	,	PUNCT
gs-1727	99	27	kinaciyan	kinaciyan	PROPN
gs-1727	99	28	t	t	PROPN
gs-1727	99	29	,	,	PUNCT
gs-1727	99	30	kromminga	kromminga	PROPN
gs-1727	99	31	a	a	X
gs-1727	99	32	,	,	PUNCT
gs-1727	99	33	konstantinou	konstantinou	PROPN
gs-1727	99	34	gn	gn	PROPN
gs-1727	99	35	,	,	PUNCT
gs-1727	99	36	makris	makris	PROPN
gs-1727	99	37	m	m	PROPN
gs-1727	99	38	,	,	PUNCT
gs-1727	99	39	metz	metz	PROPN
gs-1727	99	40	m	m	PROPN
gs-1727	99	41	,	,	PUNCT
gs-1727	99	42	skov	skov	PROPN
gs-1727	99	43	ps	ps	PROPN
gs-1727	99	44	,	,	PUNCT
gs-1727	99	45	staubach	staubach	NOUN
gs-1727	99	46	p	p	X
gs-1727	99	47	,	,	PUNCT
gs-1727	99	48	georgian	georgian	ADJ
gs-1727	99	49	scientists/ქართველი	scientists/ქართველი	NOUN
gs-1727	99	50	მეცნიერები	მეცნიერები	NOUN
gs-1727	99	51	ტ.	ტ.	VERB
gs-1727	99	52	5	5	NUM
gs-1727	99	53	n	n	PRON
gs-1727	99	54	2	2	NUM
gs-1727	99	55	,	,	PUNCT
gs-1727	99	56	2023	2023	NUM
gs-1727	99	57	115	115	NUM
gs-1727	99	58	sussman	sussman	NOUN
gs-1727	99	59	g	g	PROPN
gs-1727	99	60	,	,	PUNCT
gs-1727	99	61	zhang	zhang	PROPN
gs-1727	99	62	k	k	PROPN
gs-1727	99	63	,	,	PUNCT
gs-1727	99	64	maurer	maurer	PROPN
gs-1727	99	65	m.	m.	PROPN
gs-1727	99	66	autoimmune	autoimmune	PROPN
gs-1727	99	67	diseases	disease	NOUN
gs-1727	99	68	are	be	AUX
gs-1727	99	69	linked	link	VERB
gs-1727	99	70	to	to	PART
gs-1727	99	71	type	type	VERB
gs-1727	99	72	iib	iib	PROPN
gs-1727	99	73	autoimmune	autoimmune	PROPN
gs-1727	99	74	chronic	chronic	PROPN
gs-1727	99	75	spontaneous	spontaneous	ADJ
gs-1727	99	76	urticaria	urticaria	NOUN
gs-1727	99	77	.	.	PUNCT
gs-1727	100	1	allergy	allergy	PROPN
gs-1727	100	2	asthma	asthma	PROPN
gs-1727	100	3	immunol	immunol	PROPN
gs-1727	100	4	res	re	NOUN
gs-1727	100	5	.	.	PUNCT
gs-1727	101	1	2021jul;13(4):545	2021jul;13(4):545	NUM
gs-1727	101	2	-	-	SYM
gs-1727	101	3	559	559	NUM
gs-1727	101	4	.	.	PUNCT
gs-1727	102	1	7	7	X
gs-1727	102	2	.	.	X
gs-1727	102	3	gotua	gotua	NOUN
gs-1727	102	4	m	m	PROPN
gs-1727	102	5	,	,	PUNCT
gs-1727	102	6	agondi	agondi	PROPN
gs-1727	102	7	rc	rc	PROPN
gs-1727	102	8	,	,	PUNCT
gs-1727	102	9	cherrez	cherrez	NOUN
gs-1727	102	10	-	-	PUNCT
gs-1727	102	11	ojeda	ojeda	PROPN
gs-1727	102	12	i.	i.	PROPN
gs-1727	102	13	urticaria	urticaria	PROPN
gs-1727	102	14	and	and	CCONJ
gs-1727	102	15	comorbidities	comorbiditie	NOUN
gs-1727	102	16	.	.	PUNCT
gs-1727	103	1	indian	indian	PROPN
gs-1727	103	2	j	j	PROPN
gs-1727	103	3	skin	skin	NOUN
gs-1727	103	4	allergy	allergy	NOUN
gs-1727	103	5	2022;1:35	2022;1:35	NOUN
gs-1727	103	6	-	-	SYM
gs-1727	103	7	9	9	NUM
gs-1727	103	8	.	.	NOUN
gs-1727	103	9	8	8	NUM
gs-1727	103	10	.	.	X
gs-1727	104	1	maurer	maurer	PROPN
gs-1727	104	2	m	m	PROPN
gs-1727	104	3	,	,	PUNCT
gs-1727	104	4	eyerich	eyerich	PROPN
gs-1727	104	5	k	k	NOUN
gs-1727	104	6	,	,	PUNCT
gs-1727	104	7	eyerich	eyerich	PROPN
gs-1727	104	8	s	s	PROPN
gs-1727	104	9	,	,	PUNCT
gs-1727	104	10	ferrer	ferrer	PROPN
gs-1727	104	11	m	m	PROPN
gs-1727	104	12	,	,	PUNCT
gs-1727	104	13	gutermuth	gutermuth	PROPN
gs-1727	104	14	j	j	PROPN
gs-1727	104	15	,	,	PUNCT
gs-1727	104	16	hartmann	hartmann	PROPN
gs-1727	104	17	k	k	PROPN
gs-1727	104	18	,	,	PUNCT
gs-1727	104	19	jakob	jakob	PROPN
gs-1727	104	20	t	t	PROPN
gs-1727	104	21	,	,	PUNCT
gs-1727	104	22	kapp	kapp	PROPN
gs-1727	104	23	a	a	PROPN
gs-1727	104	24	,	,	PUNCT
gs-1727	104	25	kolkhir	kolkhir	PROPN
gs-1727	104	26	p	p	NOUN
gs-1727	104	27	,	,	PUNCT
gs-1727	104	28	larenas	larenas	PROPN
gs-1727	104	29	-	-	PUNCT
gs-1727	104	30	linnemann	linnemann	ADJ
gs-1727	104	31	d	d	NOUN
gs-1727	104	32	,	,	PUNCT
gs-1727	104	33	park	park	NOUN
gs-1727	104	34	h	h	PROPN
gs-1727	104	35	,	,	PUNCT
gs-1727	104	36	-s	-s	PROPN
gs-1727	104	37	,	,	PUNCT
gs-1727	104	38	pejler	pejler	NOUN
gs-1727	104	39	g	g	NOUN
gs-1727	104	40	,	,	PUNCT
gs-1727	104	41	sánchez	sánchez	NOUN
gs-1727	104	42	-	-	PUNCT
gs-1727	104	43	borges	borge	NOUN
gs-1727	104	44	m	m	PROPN
gs-1727	104	45	,	,	PUNCT
gs-1727	104	46	schäkel	schäkel	ADV
gs-1727	104	47	k	k	PROPN
gs-1727	104	48	,	,	PUNCT
gs-1727	104	49	simon	simon	PROPN
gs-1727	104	50	d	d	PROPN
gs-1727	104	51	,	,	PUNCT
gs-1727	104	52	simon	simon	PROPN
gs-1727	104	53	h	h	PROPN
gs-1727	104	54	,	,	PUNCT
gs-1727	104	55	-u	-u	CCONJ
gs-1727	104	56	,	,	PUNCT
gs-1727	104	57	weller	weller	PROPN
gs-1727	104	58	k	k	PROPN
gs-1727	104	59	,	,	PUNCT
gs-1727	104	60	zuberbier	zuberbier	PROPN
gs-1727	104	61	t	t	PROPN
gs-1727	104	62	,	,	PUNCT
gs-1727	104	63	metz	metz	PROPN
gs-1727	104	64	m	m	PROPN
gs-1727	104	65	:	:	PUNCT
gs-1727	104	66	urticaria	urticaria	NOUN
gs-1727	104	67	:	:	PUNCT
gs-1727	104	68	collegium	collegium	NOUN
gs-1727	104	69	internationale	internationale	NOUN
gs-1727	104	70	allergologicum	allergologicum	NOUN
gs-1727	104	71	(	(	PUNCT
gs-1727	104	72	cia	cia	PROPN
gs-1727	104	73	)	)	PUNCT
gs-1727	104	74	update	update	NOUN
gs-1727	104	75	2020	2020	NUM
gs-1727	104	76	.	.	PUNCT
gs-1727	105	1	int	int	PROPN
gs-1727	105	2	arch	arch	ADJ
gs-1727	105	3	allergy	allergy	PROPN
gs-1727	105	4	immunol	immunol	PROPN
gs-1727	105	5	2020;181:321	2020;181:321	NOUN
gs-1727	105	6	-	-	SYM
gs-1727	105	7	333	333	NUM
gs-1727	105	8	.	.	PUNCT
gs-1727	106	1	9	9	X
gs-1727	106	2	.	.	X
gs-1727	106	3	ertaş	ertaş	NOUN
gs-1727	106	4	r	r	NOUN
gs-1727	106	5	,	,	PUNCT
gs-1727	106	6	hawro	hawro	NOUN
gs-1727	106	7	t	t	PROPN
gs-1727	106	8	,	,	PUNCT
gs-1727	106	9	altrichter	altrichter	PROPN
gs-1727	106	10	s	s	PROPN
gs-1727	106	11	,	,	PUNCT
gs-1727	106	12	özyurt	özyurt	NOUN
gs-1727	106	13	k	k	NOUN
gs-1727	106	14	,	,	PUNCT
gs-1727	106	15	erol	erol	PROPN
gs-1727	106	16	k	k	PROPN
gs-1727	106	17	,	,	PUNCT
gs-1727	106	18	ketenci	ketenci	PROPN
gs-1727	106	19	ertaş	ertaş	NOUN
gs-1727	106	20	ş	ş	PROPN
gs-1727	106	21	,	,	PUNCT
gs-1727	106	22	maurer	maurer	PROPN
gs-1727	106	23	m.	m.	PROPN
gs-1727	106	24	antinuclear	antinuclear	PROPN
gs-1727	106	25	antibodies	antibody	NOUN
gs-1727	106	26	are	be	AUX
gs-1727	106	27	common	common	ADJ
gs-1727	106	28	and	and	CCONJ
gs-1727	106	29	linked	link	VERB
gs-1727	106	30	to	to	ADP
gs-1727	106	31	poor	poor	ADJ
gs-1727	106	32	response	response	NOUN
gs-1727	106	33	to	to	AUX
gs-1727	106	34	omalizumab	omalizumab	NOUN
gs-1727	106	35	treatment	treatment	NOUN
gs-1727	106	36	in	in	ADP
gs-1727	106	37	patients	patient	NOUN
gs-1727	106	38	with	with	ADP
gs-1727	106	39	csu	csu	PROPN
gs-1727	106	40	.	.	PUNCT
gs-1727	107	1	allergy	allergy	PROPN
gs-1727	107	2	.	.	PUNCT
gs-1727	108	1	2020	2020	NUM
gs-1727	108	2	feb;75(2):468	feb;75(2):468	NOUN
gs-1727	108	3	-	-	PUNCT
gs-1727	108	4	470	470	NUM
gs-1727	108	5	.	.	PUNCT
gs-1727	109	1	10	10	NUM
gs-1727	109	2	.	.	PUNCT
gs-1727	109	3	zhiron	zhiron	PROPN
gs-1727	109	4	du	du	PROPN
gs-1727	109	5	,	,	PUNCT
gs-1727	109	6	yuxiang	yuxiang	PROPN
gs-1727	109	7	zhi	zhi	PROPN
gs-1727	109	8	,	,	PUNCT
gs-1727	109	9	md	md	PROPN
gs-1727	109	10	.	.	PROPN
gs-1727	109	11	predictors	predictor	NOUN
gs-1727	109	12	of	of	ADP
gs-1727	109	13	response	response	NOUN
gs-1727	109	14	to	to	ADP
gs-1727	109	15	omalizumab	omalizumab	NOUN
gs-1727	109	16	in	in	ADP
gs-1727	109	17	chrinic	chrinic	ADJ
gs-1727	109	18	spontaneus	spontaneus	NOUN
gs-1727	109	19	urticaria	urticaria	PROPN
gs-1727	109	20	.	.	PUNCT
gs-1727	110	1	journal	journal	PROPN
gs-1727	110	2	of	of	ADP
gs-1727	110	3	allergy	allergy	NOUN
gs-1727	110	4	and	and	CCONJ
gs-1727	110	5	clinical	clinical	ADJ
gs-1727	110	6	immunology	immunology	NOUN
gs-1727	110	7	,	,	PUNCT
gs-1727	110	8	volume	volume	NOUN
gs-1727	110	9	151	151	NUM
gs-1727	110	10	,	,	PUNCT
gs-1727	110	11	issue	issue	NOUN
gs-1727	110	12	2	2	NUM
gs-1727	110	13	,	,	PUNCT
gs-1727	110	14	supplement	supplement	NOUN
gs-1727	110	15	,	,	PUNCT
gs-1727	110	16	ab207	ab207	PROPN
gs-1727	110	17	february	february	PROPN
gs-1727	110	18	2023	2023	NUM
gs-1727	110	19	.	.	PUNCT
gs-1727	111	1	11	11	NUM
gs-1727	111	2	.	.	PUNCT
gs-1727	111	3	ertas	ertas	PROPN
gs-1727	111	4	r	r	PROPN
gs-1727	111	5	,	,	PUNCT
gs-1727	111	6	ozyurt	ozyurt	NOUN
gs-1727	111	7	k	k	NOUN
gs-1727	111	8	,	,	PUNCT
gs-1727	111	9	atasoy	atasoy	PROPN
gs-1727	111	10	m	m	PROPN
gs-1727	111	11	,	,	PUNCT
gs-1727	111	12	hawro	hawro	PROPN
gs-1727	111	13	t	t	PROPN
gs-1727	111	14	,	,	PUNCT
gs-1727	111	15	maurer	maurer	PROPN
gs-1727	111	16	m.	m.	VERB
gs-1727	111	17	the	the	DET
gs-1727	111	18	clinical	clinical	ADJ
gs-1727	111	19	response	response	NOUN
gs-1727	111	20	to	to	ADP
gs-1727	111	21	omalizumab	omalizumab	NOUN
gs-1727	111	22	in	in	ADP
gs-1727	111	23	chronic	chronic	ADJ
gs-1727	111	24	spontaneous	spontaneous	ADJ
gs-1727	111	25	urticaria	urticaria	NOUN
gs-1727	111	26	patients	patient	NOUN
gs-1727	111	27	is	be	AUX
gs-1727	111	28	linked	link	VERB
gs-1727	111	29	to	to	ADP
gs-1727	111	30	and	and	CCONJ
gs-1727	111	31	predicted	predict	VERB
gs-1727	111	32	by	by	ADP
gs-1727	111	33	ige	ige	PROPN
gs-1727	111	34	levels	level	NOUN
gs-1727	111	35	and	and	CCONJ
gs-1727	111	36	their	their	PRON
gs-1727	111	37	change	change	NOUN
gs-1727	111	38	.	.	PUNCT
gs-1727	112	1	allergy	allergy	NOUN
gs-1727	112	2	2018;73(3):705	2018;73(3):705	PROPN
gs-1727	112	3	-	-	PUNCT
gs-1727	112	4	712	712	NUM
gs-1727	112	5	.	.	PUNCT
gs-1727	112	6	12	12	NUM
gs-1727	112	7	.	.	PUNCT
gs-1727	113	1	weller	weller	PROPN
gs-1727	113	2	k	k	PROPN
gs-1727	113	3	,	,	PUNCT
gs-1727	113	4	ohanyan	ohanyan	PROPN
gs-1727	113	5	t	t	PROPN
gs-1727	113	6	,	,	PUNCT
gs-1727	113	7	hawro	hawro	PROPN
gs-1727	113	8	t	t	PROPN
gs-1727	113	9	,	,	PUNCT
gs-1727	113	10	et	et	PROPN
gs-1727	113	11	al	al	PROPN
gs-1727	113	12	.	.	PROPN
gs-1727	114	1	total	total	PROPN
gs-1727	114	2	ige	ige	PROPN
gs-1727	114	3	levels	level	NOUN
gs-1727	114	4	are	be	AUX
gs-1727	114	5	linked	link	VERB
gs-1727	114	6	to	to	ADP
gs-1727	114	7	the	the	DET
gs-1727	114	8	response	response	NOUN
gs-1727	114	9	of	of	ADP
gs-1727	114	10	chronic	chronic	ADJ
gs-1727	114	11	spontaneous	spontaneous	ADJ
gs-1727	114	12	urticaria	urticaria	NOUN
gs-1727	114	13	patients	patient	NOUN
gs-1727	114	14	to	to	PART
gs-1727	114	15	omalizumab	omalizumab	VERB
gs-1727	114	16	.	.	PUNCT
gs-1727	115	1	allergy	allergy	NOUN
gs-1727	115	2	2018;73(12):2406	2018;73(12):2406	NUM
gs-1727	115	3	-	-	SYM
gs-1727	115	4	2408	2408	NUM
gs-1727	115	5	.	.	PUNCT
gs-1727	116	1	13	13	NUM
gs-1727	116	2	.	.	X
gs-1727	116	3	asero	asero	PROPN
gs-1727	116	4	r.	r.	PROPN
gs-1727	116	5	chronic	chronic	PROPN
gs-1727	116	6	spontaneous	spontaneous	ADJ
gs-1727	116	7	urticaria	urticaria	NOUN
gs-1727	116	8	treated	treat	VERB
gs-1727	116	9	with	with	ADP
gs-1727	116	10	omalizumab	omalizumab	NOUN
gs-1727	116	11	:	:	PUNCT
gs-1727	116	12	what	what	PRON
gs-1727	116	13	differentiates	differentiate	VERB
gs-1727	116	14	early	early	ADV
gs-1727	116	15	from	from	ADP
gs-1727	116	16	late	late	ADJ
gs-1727	116	17	responders	responder	NOUN
gs-1727	116	18	?	?	PUNCT
gs-1727	117	1	eur	eur	PROPN
gs-1727	117	2	ann	ann	PROPN
gs-1727	117	3	allergy	allergy	PROPN
gs-1727	117	4	clin	clin	PROPN
gs-1727	117	5	immunol	immunol	PROPN
gs-1727	117	6	.	.	PUNCT
gs-1727	118	1	2020	2020	NUM
gs-1727	118	2	.	.	PUNCT
gs-1727	119	1	14	14	NUM
gs-1727	119	2	.	.	X
gs-1727	119	3	asero	asero	PROPN
gs-1727	119	4	,	,	PUNCT
gs-1727	119	5	r.	r.	PROPN
gs-1727	119	6	,	,	PUNCT
gs-1727	119	7	ferrucci	ferrucci	NOUN
gs-1727	119	8	,	,	PUNCT
gs-1727	119	9	s.	s.	PROPN
gs-1727	119	10	m.	m.	PROPN
gs-1727	119	11	,	,	PUNCT
gs-1727	119	12	calzari	calzari	NOUN
gs-1727	119	13	,	,	PUNCT
gs-1727	119	14	p.	p.	PROPN
gs-1727	119	15	,	,	PUNCT
gs-1727	119	16	consonni	consonni	PROPN
gs-1727	119	17	,	,	PUNCT
gs-1727	119	18	d.	d.	PROPN
gs-1727	119	19	,	,	PUNCT
gs-1727	119	20	&	&	CCONJ
gs-1727	119	21	cugno	cugno	PROPN
gs-1727	119	22	,	,	PUNCT
gs-1727	119	23	m.	m.	NOUN
gs-1727	119	24	(	(	PUNCT
gs-1727	119	25	2023	2023	NUM
gs-1727	119	26	)	)	PUNCT
gs-1727	119	27	.	.	PUNCT
gs-1727	120	1	thyroid	thyroid	NOUN
gs-1727	120	2	autoimmunity	autoimmunity	NOUN
gs-1727	120	3	in	in	ADP
gs-1727	120	4	csu	csu	PROPN
gs-1727	120	5	:	:	PUNCT
gs-1727	120	6	a	a	DET
gs-1727	120	7	potential	potential	ADJ
gs-1727	120	8	marker	marker	NOUN
gs-1727	120	9	of	of	ADP
gs-1727	120	10	omalizumab	omalizumab	NOUN
gs-1727	120	11	response	response	NOUN
gs-1727	120	12	?	?	PUNCT
gs-1727	121	1	international	international	ADJ
gs-1727	121	2	journal	journal	NOUN
gs-1727	121	3	of	of	ADP
gs-1727	121	4	molecular	molecular	ADJ
gs-1727	121	5	sciences	science	NOUN
gs-1727	121	6	,	,	PUNCT
gs-1727	121	7	24(8	24(8	NUM
gs-1727	121	8	)	)	PUNCT
gs-1727	121	9	,	,	PUNCT
gs-1727	121	10	7491	7491	NUM
gs-1727	121	11	.	.	PUNCT
gs-1727	122	1	i	i	PRON
gs-1727	122	2	და	და	PROPN
gs-1727	122	3	iib	iib	PROPN
gs-1727	122	4	ტიპის	ტიპის	PROPN
gs-1727	122	5	აუტოიმუნურობა	აუტოიმუნურობა	PROPN
gs-1727	122	6	ქრონიკული	ქრონიკული	VERB
gs-1727	122	7	სპონტანური	სპონტანური	NOUN
gs-1727	122	8	ურტიკარიით	ურტიკარიით	PROPN
gs-1727	122	9	პაციენტებში	პაციენტებში	NOUN
gs-1727	122	10	:	:	PUNCT
gs-1727	122	11	ომალიზუმაბით	ომალიზუმაბით	PROPN
gs-1727	122	12	მკურნალობის	მკურნალობის	PROPN
gs-1727	122	13	ეფექტურობის	ეფექტურობის	PROPN
gs-1727	122	14	შეფასება	შეფასება	PROPN
gs-1727	122	15	ბიძინა	ბიძინა	PROPN
gs-1727	122	16	კულუმბეგოვი	კულუმბეგოვი	NOUN
gs-1727	122	17	1,2	1,2	NUM
gs-1727	122	18	,	,	PUNCT
gs-1727	122	19	მაია	მაია	NOUN
gs-1727	122	20	გოთუა	გოთუა	NOUN
gs-1727	122	21	1	1	NUM
gs-1727	122	22	,	,	PUNCT
gs-1727	122	23	თინათინ	თინათინ	NOUN
gs-1727	122	24	ჩიქოვანი	ჩიქოვანი	NOUN
gs-1727	122	25	2	2	NUM
gs-1727	122	26	1ალერგიისა	1ალერგიისა	NUM
gs-1727	122	27	და	და	PROPN
gs-1727	122	28	იმუნოლოგიის	იმუნოლოგიის	PROPN
gs-1727	122	29	ცენტრი	ცენტრი	NOUN
gs-1727	122	30	;	;	PUNCT
gs-1727	122	31	2თბილისის	2თბილისის	NUM
gs-1727	122	32	სახელმწიფო	სახელმწიფო	NOUN
gs-1727	122	33	სამედიცინო	სამედიცინო	NOUN
gs-1727	122	34	უნივერსიტეტი	უნივერსიტეტი	PROPN
gs-1727	122	35	კვლევის	კვლევის	NOUN
gs-1727	122	36	მიზანი	მიზანი	VERB
gs-1727	122	37	იყო	იყო	ADJ
gs-1727	123	1	i	i	PRON
gs-1727	123	2	და	და	VERB
gs-1727	123	3	iiბ	iiბ	PROPN
gs-1727	123	4	ტიპის	ტიპის	NOUN
gs-1727	123	5	აუტოიმუნურობის	აუტოიმუნურობის	PROPN
gs-1727	123	6	მქონე	მქონე	PROPN
gs-1727	123	7	ქრონიკული	ქრონიკული	VERB
gs-1727	124	1	სპონტანური	სპონტანური	NOUN
gs-1727	124	2	ურტიკარიით	ურტიკარიით	NOUN
gs-1727	124	3	(	(	PUNCT
gs-1727	124	4	ქსუ	ქსუ	NOUN
gs-1727	124	5	)	)	PUNCT
gs-1727	124	6	დაავადებულ	დაავადებულ	NOUN
gs-1727	124	7	პაციენტებში	პაციენტებში	NOUN
gs-1727	124	8	ომალიზუმაბზე	ომალიზუმაბზე	PROPN
gs-1727	124	9	კლინიკური	კლინიკური	PROPN
gs-1727	124	10	პასუხის	პასუხის	PROPN
gs-1727	124	11	შეფასება.	შეფასება.	PROPN
gs-1727	124	12	რეტროსპექტული	რეტროსპექტული	PROPN
gs-1727	124	13	კვლევა	კვლევა	PROPN
gs-1727	124	14	ჩატარდა	ჩატარდა	PROPN
gs-1727	124	15	39	39	NUM
gs-1727	124	16	პაციენტზე	პაციენტზე	ADJ
gs-1727	124	17	(	(	PUNCT
gs-1727	124	18	95	95	NUM
gs-1727	124	19	%	%	NOUN
gs-1727	124	20	ქალი	ქალი	NOUN
gs-1727	124	21	,	,	PUNCT
gs-1727	124	22	5	5	NUM
gs-1727	124	23	%	%	NOUN
gs-1727	124	24	მამაკაცი	მამაკაცი	NOUN
gs-1727	124	25	,	,	PUNCT
gs-1727	124	26	საშუალო	საშუალო	ADJ
gs-1727	124	27	ასაკი	ასაკი	PROPN
gs-1727	124	28	35.82	35.82	NUM
gs-1727	124	29	წელი	წელი	NOUN
gs-1727	124	30	)	)	PUNCT
gs-1727	124	31	,	,	PUNCT
gs-1727	124	32	რომლებიც	რომლებიც	ADP
gs-1727	124	33	2019	2019	NUM
gs-1727	124	34	წლის	წლის	NOUN
gs-1727	124	35	სექტემბრიდან	სექტემბრიდან	PROPN
gs-1727	124	36	2022	2022	NUM
gs-1727	124	37	წლის	წლის	NOUN
gs-1727	124	38	დეკემბრამდე	დეკემბრამდე	NOUN
gs-1727	124	39	მკურნალობდნენ	მკურნალობდნენ	NOUN
gs-1727	124	40	ალერგიისა	ალერგიისა	PROPN
gs-1727	124	41	და	და	PROPN
gs-1727	124	42	იმუნოლოგიის	იმუნოლოგიის	ADJ
gs-1727	124	43	ცენტრში	ცენტრში	NOUN
gs-1727	124	44	(	(	PUNCT
gs-1727	124	45	თბილისი	თბილისი	PROPN
gs-1727	124	46	,	,	PUNCT
gs-1727	124	47	საქართველო	საქართველო	PROPN
gs-1727	124	48	)	)	PUNCT
gs-1727	124	49	.	.	PUNCT
gs-1727	125	1	აუტოიმუნურობის	აუტოიმუნურობის	ADJ
gs-1727	125	2	მარკერებად	მარკერებად	PROPN
gs-1727	125	3	გამოვიყენეთ	გამოვიყენეთ	PROPN
gs-1727	125	4	შრატში	შრატში	PROPN
gs-1727	125	5	საერთო	საერთო	PROPN
gs-1727	125	6	ige-ს	ige-ს	PROPN
gs-1727	125	7	დონე	დონე	PROPN
gs-1727	125	8	და	და	PROPN
gs-1727	125	9	ana	ana	PROPN
gs-1727	125	10	ანტისხეულების	ანტისხეულების	PROPN
gs-1727	125	11	არსებობა.	არსებობა.	PROPN
gs-1727	125	12	კვლევაში	კვლევაში	PROPN
gs-1727	125	13	შედიოდნენ	შედიოდნენ	PROPN
gs-1727	125	14	პაციენტები	პაციენტები	PROPN
gs-1727	125	15	,	,	PUNCT
gs-1727	125	16	რომლებსაც	რომლებსაც	NOUN
gs-1727	125	17	,	,	PUNCT
gs-1727	125	18	არასედაციური	არასედაციური	NOUN
gs-1727	125	19	georgian	georgian	PROPN
gs-1727	125	20	scientists/ქართველი	scientists/ქართველი	PROPN
gs-1727	125	21	მეცნიერები	მეცნიერები	NOUN
gs-1727	125	22	ტ.	ტ.	VERB
gs-1727	125	23	5	5	NUM
gs-1727	125	24	n	n	PRON
gs-1727	125	25	2	2	NUM
gs-1727	125	26	,	,	PUNCT
gs-1727	125	27	2023	2023	NUM
gs-1727	125	28	116	116	NUM
gs-1727	125	29	ანტიჰისტამინური	ანტიჰისტამინური	PROPN
gs-1727	125	30	პრეპარატების	პრეპარატების	ADJ
gs-1727	125	31	ოთხმაგი	ოთხმაგი	PROPN
gs-1727	125	32	დოზით	დოზით	PROPN
gs-1727	125	33	გამოყენების	გამოყენების	PROPN
gs-1727	125	34	მიუხედავად	მიუხედავად	PROPN
gs-1727	125	35	,	,	PUNCT
gs-1727	125	36	ჰქონდათ	ჰქონდათ	PROPN
gs-1727	125	37	დაავადების	დაავადების	PROPN
gs-1727	125	38	მაღალი	მაღალი	PROPN
gs-1727	125	39	აქტივობა.	აქტივობა.	PROPN
gs-1727	125	40	პაციენტებს	პაციენტებს	PROPN
gs-1727	125	41	,	,	PUNCT
gs-1727	125	42	საერთაშორისო	საერთაშორისო	NOUN
gs-1727	125	43	გაიდლაინების	გაიდლაინების	ADJ
gs-1727	125	44	მიხედვით	მიხედვით	NOUN
gs-1727	125	45	,	,	PUNCT
gs-1727	125	46	დაენიშნათ	დაენიშნათ	NOUN
gs-1727	125	47	ომალიზუმაბი	ომალიზუმაბი	VERB
gs-1727	125	48	4	4	NUM
gs-1727	125	49	კვირის	კვირის	NOUN
gs-1727	125	50	ინტერვალით	ინტერვალით	NOUN
gs-1727	125	51	მინიმუმ	მინიმუმ	VERB
gs-1727	125	52	3	3	NUM
gs-1727	125	53	თვის	თვის	PROPN
gs-1727	125	54	განმავლობაში.	განმავლობაში.	VERB
gs-1727	125	55	დაავადების	დაავადების	PROPN
gs-1727	125	56	აქტივობა	აქტივობა	ADJ
gs-1727	125	57	განისაზღვრა	განისაზღვრა	PROPN
gs-1727	125	58	ურტიკარიის	ურტიკარიის	PROPN
gs-1727	125	59	აქტივობის	აქტივობის	ADV
gs-1727	125	60	ქულის	ქულის	VERB
gs-1727	125	61	(	(	PUNCT
gs-1727	125	62	uas7	uas7	PROPN
gs-1727	125	63	)	)	PUNCT
gs-1727	125	64	გამოყენებით.	გამოყენებით.	VERB
gs-1727	126	1	ქსუ-ის	ქსუ-ის	ADP
gs-1727	126	2	აქტივობის	აქტივობის	ADV
gs-1727	126	3	მიხედვით	მიხედვით	NOUN
gs-1727	126	4	პაციენტები	პაციენტები	NOUN
gs-1727	126	5	დაიყო	დაიყო	NOUN
gs-1727	126	6	სამ	სამ	VERB
gs-1727	126	7	ჯგუფად	ჯგუფად	ADV
gs-1727	126	8	:	:	PUNCT
gs-1727	126	9	დაბალი	დაბალი	ADJ
gs-1727	126	10	,	,	PUNCT
gs-1727	126	11	საშუალო	საშუალო	ADJ
gs-1727	126	12	და	და	NOUN
gs-1727	126	13	მაღალი	მაღალი	PROPN
gs-1727	126	14	დაავადების	დაავადების	PROPN
gs-1727	126	15	აქტივობით.	აქტივობით.	PROPN
gs-1727	126	16	პასუხი	პასუხი	NOUN
gs-1727	126	17	ომალიზუმაბზე	ომალიზუმაბზე	PROPN
gs-1727	126	18	შეფასდა	შეფასდა	PROPN
gs-1727	126	19	როგორც	როგორც	PROPN
gs-1727	126	20	:	:	PUNCT
gs-1727	126	21	არამოპასუხე	არამოპასუხე	NOUN
gs-1727	126	22	,	,	PUNCT
gs-1727	126	23	ნაწილობრივ	ნაწილობრივ	PROPN
gs-1727	126	24	მოპასუხე	მოპასუხე	PROPN
gs-1727	126	25	და	და	PROPN
gs-1727	126	26	სრულად	სრულად	VERB
gs-1727	126	27	მოპასუხე.	მოპასუხე.	PROPN
gs-1727	126	28	შედეგებმა	შედეგებმა	PROPN
gs-1727	126	29	აჩვენა	აჩვენა	PROPN
gs-1727	126	30	,	,	PUNCT
gs-1727	126	31	რომ	რომ	PROPN
gs-1727	127	1	i	i	PRON
gs-1727	127	2	ტიპის	ტიპის	VERB
gs-1727	127	3	აუტოიმუნურობის	აუტოიმუნურობის	PROPN
gs-1727	127	4	შემთხვევაში	შემთხვევაში	PROPN
gs-1727	127	5	სრულად	სრულად	VERB
gs-1727	127	6	მოპასუხე	მოპასუხე	PROPN
gs-1727	127	7	პაციენტების	პაციენტების	PROPN
gs-1727	127	8	პროცენტული	პროცენტული	PROPN
gs-1727	127	9	მაჩვენებელი	მაჩვენებელი	NOUN
gs-1727	127	10	სტატისტიკურად	სტატისტიკურად	NOUN
gs-1727	127	11	სარწმუნოდ	სარწმუნოდ	NOUN
gs-1727	127	12	მაღალია	მაღალია	VERB
gs-1727	127	13	,	,	PUNCT
gs-1727	127	14	ვიდრე	ვიდრე	NOUN
gs-1727	127	15	iiბ	iiბ	NOUN
gs-1727	127	16	ტიპის	ტიპის	NOUN
gs-1727	127	17	შემთხვევაში	შემთხვევაში	NOUN
gs-1727	127	18	(	(	PUNCT
gs-1727	127	19	55.5%/18.3	55.5%/18.3	NUM
gs-1727	127	20	%	%	NOUN
gs-1727	127	21	)	)	PUNCT
gs-1727	127	22	.	.	PUNCT
gs-1727	128	1	ომალიზუმაბზე	ომალიზუმაბზე	PROPN
gs-1727	128	2	არამოპასუხეთა	არამოპასუხეთა	PROPN
gs-1727	128	3	სიხშირე	სიხშირე	PROPN
gs-1727	128	4	უფრო	უფრო	PROPN
gs-1727	128	5	მაღალი	მაღალი	PROPN
gs-1727	128	6	იყო	იყო	PRON
gs-1727	128	7	iiბ	iiბ	PROPN
gs-1727	128	8	ტიპის	ტიპის	NOUN
gs-1727	128	9	დროს	დროს	PROPN
gs-1727	128	10	,	,	PUNCT
gs-1727	128	11	ვიდრე	ვიდრე	NOUN
gs-1727	128	12	i	i	PRON
gs-1727	128	13	ტიპის	ტიპის	NOUN
gs-1727	128	14	შემთხვევაში	შემთხვევაში	NOUN
gs-1727	128	15	(	(	PUNCT
gs-1727	128	16	72.7%/18.5	72.7%/18.5	NUM
gs-1727	128	17	%	%	NOUN
gs-1727	128	18	)	)	PUNCT
gs-1727	128	19	.	.	PUNCT
gs-1727	129	1	მედიანური	მედიანური	PROPN
gs-1727	129	2	საერთო	საერთო	PROPN
gs-1727	129	3	ige	ige	PROPN
gs-1727	129	4	დონე	დონე	PROPN
gs-1727	129	5	მნიშვნელოვნად	მნიშვნელოვნად	PROPN
gs-1727	129	6	მაღალი	მაღალი	PROPN
gs-1727	129	7	იყო	იყო	PROPN
gs-1727	130	1	i	i	PROPN
gs-1727	130	2	ტიპის	ტიპის	NOUN
gs-1727	130	3	დროს	დროს	VERB
gs-1727	130	4	,	,	PUNCT
gs-1727	130	5	ვიდრე	ვიდრე	NOUN
gs-1727	130	6	iiბ	iiბ	NOUN
gs-1727	130	7	ტიპის	ტიპის	NOUN
gs-1727	130	8	შემთხვევაში	შემთხვევაში	NOUN
gs-1727	130	9	(	(	PUNCT
gs-1727	130	10	138	138	NUM
gs-1727	130	11	vs.	vs.	ADP
gs-1727	130	12	23.95	23.95	NUM
gs-1727	130	13	ku	ku	PROPN
gs-1727	130	14	/	/	SYM
gs-1727	130	15	i	i	PROPN
gs-1727	130	16	)	)	PUNCT
gs-1727	130	17	.	.	PUNCT
gs-1727	131	1	დაავადების	დაავადების	PROPN
gs-1727	131	2	ხანგრძლივობა	ხანგრძლივობა	PROPN
gs-1727	131	3	მნიშვნელოვნად	მნიშვნელოვნად	PROPN
gs-1727	131	4	უფრო	უფრო	PROPN
gs-1727	131	5	ნაკლები	ნაკლები	PROPN
gs-1727	131	6	იყო	იყო	VERB
gs-1727	131	7	i	i	PRON
gs-1727	131	8	ტიპის	ტიპის	NOUN
gs-1727	131	9	,	,	PUNCT
gs-1727	131	10	ვიდრე	ვიდრე	NOUN
gs-1727	131	11	iiბ	iiბ	PROPN
gs-1727	131	12	ტიპის	ტიპის	NOUN
gs-1727	131	13	დროს	დროს	PROPN
gs-1727	131	14	(	(	PUNCT
gs-1727	131	15	9	9	NUM
gs-1727	131	16	vs.	vs.	ADP
gs-1727	131	17	27	27	NUM
gs-1727	131	18	თვე	თვე	NOUN
gs-1727	131	19	)	)	PUNCT
gs-1727	131	20	.	.	PUNCT
gs-1727	132	1	ამ	ამ	AUX
gs-1727	132	2	ორ	ორ	PROPN
gs-1727	132	3	ჯგუფს	ჯგუფს	PROPN
gs-1727	132	4	შორის	შორის	PROPN
gs-1727	132	5	მნიშვნელოვანი	მნიშვნელოვანი	PROPN
gs-1727	132	6	განსხვავება	განსხვავება	PROPN
gs-1727	132	7	არ	არ	PROPN
gs-1727	132	8	დაფიქსირებულა	დაფიქსირებულა	PROPN
gs-1727	132	9	ასაკის	ასაკის	PROPN
gs-1727	132	10	,	,	PUNCT
gs-1727	132	11	ანგიოედემის	ანგიოედემის	NOUN
gs-1727	132	12	,	,	PUNCT
gs-1727	132	13	c-რეაქტიული	c-რეაქტიული	PROPN
gs-1727	132	14	ცილის	ცილის	VERB
gs-1727	132	15	დონის	დონის	PROPN
gs-1727	132	16	,	,	PUNCT
gs-1727	132	17	h.pylori	h.pylori	NOUN
gs-1727	132	18	ინფექციის	ინფექციის	NOUN
gs-1727	132	19	სიხშირის	სიხშირის	NOUN
gs-1727	132	20	,	,	PUNCT
gs-1727	132	21	ანტი-tpo	ანტი-tpo	PROPN
gs-1727	132	22	igg	igg	PROPN
gs-1727	132	23	დონის	დონის	PROPN
gs-1727	132	24	,	,	PUNCT
gs-1727	132	25	ეოზინოპენიის	ეოზინოპენიის	PROPN
gs-1727	132	26	და	და	PROPN
gs-1727	132	27	ბაზოპენიის	ბაზოპენიის	PROPN
gs-1727	132	28	თვალსაზრისით.	თვალსაზრისით.	PROPN
gs-1727	132	29	შეიძლება	შეიძლება	PROPN
gs-1727	132	30	დავასკვნათ	დავასკვნათ	VERB
gs-1727	132	31	,	,	PUNCT
gs-1727	133	1	რომ	რომ	PROPN
gs-1727	133	2	კლინიკური	კლინიკური	PROPN
gs-1727	133	3	პასუხი	პასუხი	VERB
gs-1727	133	4	ომალიზუმაბზე	ომალიზუმაბზე	PROPN
gs-1727	133	5	ქსუ-ის	ქსუ-ის	PROPN
gs-1727	133	6	აუტოიმუნურობის	აუტოიმუნურობის	ADJ
gs-1727	133	7	ტიპის	ტიპის	NOUN
gs-1727	133	8	მიხედვით	მიხედვით	NOUN
gs-1727	133	9	განსხვებულია.	განსხვებულია.	ADV
gs-1727	134	1	i	i	PRON
gs-1727	134	2	ტიპის	ტიპის	VERB
gs-1727	134	3	აუტოიმუნურ	აუტოიმუნურ	PROPN
gs-1727	134	4	პაციენტებს	პაციენტებს	PROPN
gs-1727	134	5	აქვთ	აქვთ	PROPN
gs-1727	134	6	უკეთესი	უკეთესი	PROPN
gs-1727	134	7	პასუხი	პასუხი	NOUN
gs-1727	134	8	ომალიზუმაბზე	ომალიზუმაბზე	PROPN
gs-1727	134	9	,	,	PUNCT
gs-1727	134	10	ვიდრე	ვიდრე	NOUN
gs-1727	134	11	iiბ	iiბ	PROPN
gs-1727	134	12	ტიპისას.	ტიპისას.	PROPN
gs-1727	134	13	ასევე	ასევე	PROPN
gs-1727	135	1	დაავადების	დაავადების	PROPN
gs-1727	135	2	ხანგრძლივობა	ხანგრძლივობა	PROPN
gs-1727	136	1	i	i	PRON
gs-1727	136	2	ტიპის	ტიპის	AUX
gs-1727	136	3	აუტოიმუნურ	აუტოიმუნურ	VERB
gs-1727	136	4	ჯგუფში	ჯგუფში	PROPN
gs-1727	136	5	მნიშვნელოვნად	მნიშვნელოვნად	PROPN
gs-1727	136	6	ნაკლებია	ნაკლებია	PROPN
gs-1727	136	7	ვიდრე	ვიდრე	NOUN
gs-1727	136	8	მეორე	მეორე	VERB
gs-1727	136	9	ჯგუფში.	ჯგუფში.	VERB
gs-1727	136	10	საჭიროა	საჭიროა	PROPN
gs-1727	136	11	შემდგომი	შემდგომი	NOUN
gs-1727	136	12	კვლევები	კვლევები	NOUN
gs-1727	136	13	,	,	PUNCT
gs-1727	136	14	რათა	რათა	PROPN
gs-1727	136	15	შეფასდეს	შეფასდეს	PROPN
gs-1727	136	16	მექანიზმი	მექანიზმი	PROPN
gs-1727	136	17	,	,	PUNCT
gs-1727	137	1	რომელიც	რომელიც	ADJ
gs-1727	137	2	საფუძვლად	საფუძვლად	ADJ
gs-1727	137	3	უდევს	უდევს	VERB
gs-1727	137	4	ომალიზუმაბზე	ომალიზუმაბზე	PROPN
gs-1727	137	5	რეაგირების	რეაგირების	PROPN
gs-1727	138	1	განსხვავებულობას	განსხვავებულობას	PROPN
gs-1727	138	2	და	და	PROPN
gs-1727	138	3	სხვადასხვა	სხვადასხვა	PROPN
gs-1727	138	4	ტიპის	ტიპის	NOUN
gs-1727	138	5	აუტოიმუნური	აუტოიმუნური	PROPN
gs-1727	138	6	პაციენტებისთვის	პაციენტებისთვის	PROPN
gs-1727	138	7	მკურნალობის	მკურნალობის	PROPN
gs-1727	138	8	სხვადასხვა	სხვადასხვა	PROPN
gs-1727	138	9	ვარიანტების	ვარიანტების	PROPN
gs-1727	138	10	გამოყენებას.	გამოყენებას.	PROPN
gs-1727	138	11	საკვანძო	საკვანძო	PROPN
gs-1727	138	12	სიტყვები	სიტყვები	NOUN
gs-1727	138	13	:	:	PUNCT
gs-1727	138	14	ქრონიკული	ქრონიკული	PROPN
gs-1727	138	15	სპოინტანური	სპოინტანური	PROPN
gs-1727	138	16	ურტიკარია	ურტიკარია	PROPN
gs-1727	138	17	,	,	PUNCT
gs-1727	138	18	ომალიზუმაბი	ომალიზუმაბი	PROPN
gs-1727	138	19	,	,	PUNCT
gs-1727	138	20	i	i	PRON
gs-1727	138	21	და	და	VERB
gs-1727	138	22	iiბ	iiბ	PROPN
gs-1727	138	23	ტიპის	ტიპის	NOUN
gs-1727	138	24	აუტოიმუნურობა	აუტოიმუნურობა	NOUN